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Abstract
Acetylcholine-binding protein (AChBP) is a water-soluble novel protein with a 
high sequence similarity (15-30% identity) to ligand-gated ion channel (LGIC) receptors. 
The crystal structure of AChBP is used to study the extracellular domain of the 
pentameric LGICs such as nicotinic acetylcholine receptors (nAChRs) and 5- 
hydroxytryptamine type 3 receptors (5-HT3Rs); and homology models have been 
developed to study receptor-ligand interactions. The 5-HT3 serotonin receptors are 
potential therapeutic targets for multiple nervous system disorders such as alcohol and 
drug dependence, anxiety, depression, schizophrenia, sleep, cognition, memory, and 
chemotherapy-induced and post-operative nausea and vomiting. Therefore, the ligands 
that target the 5-HT3Rs are considered powerful therapeutic agents. As such, 5-HT3 
serotonin receptors have been the targets of drug discovery efforts. The main objective 
of the current protein engineering project was to develop a soluble serotonin-binding 
protein using AChBP, which would mimic the specificity of the native 5-HT3 serotonin 
receptor. Once developed, this soluble protein would be used as a model to design an 
array of receptors, which could be placed on biosensors for high-throughput drug 
screening (HTDS).
The results of site-directed mutagenesis of AChBP demonstrated that mutation of 
certain AChBP residues to its equivalent in serotonin resulted in an increased affinity of 
AChBP for serotonin ligands, and that each individual mutation increased the affinity of 
AChBP to a certain degree. It indicates that this approach is going in the right direction 
but multiple mutations will probably be needed to get to an AChBP whose affinity is 
equivalent to wild-type serotonin. In addition, the most significant changes appeared to 
be in the C-loop as it produced the largest increase in affinity of AChBP for serotonin 
agonists. The results also support the proposed C-loop closure model for the receptor, 
and based on data presented here, a new alignment of the C-loop is suggested.
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Chapter 1: Introduction
1.1 Ligand-gated Ion Channels (LGICs)
Living cells are surrounded by membranes which are involved in the interaction 
of the cell with its environment. Ion channels are located within the membrane of most 
cells and many intracellular organelles. They are often described as narrow tunnels that 
allow only ions of certain size and/or charge to pass through and be transported across 
the membrane; a characteristic called ‘selective permeability.’ However, some channels 
are permeable to passage of ions that share a common charge, such as positive 
(cation) or negative (anion). In many ion channels, passage through the ion pore is 
controlled by a ‘gate’ which may be opened or closed in response to chemical or 
electrical signals, temperature, etc. (1).
Ion channels are broadly divided into voltage-gated and ligand-gated ion 
channels. Ligand-gated ion channels (LGICs) or ionotropic receptors are 
transmembrane ion channel proteins which open in response to binding of a ligand, 
such as a neurotransmitter, to allow passage of ions such as Na+, Ca2+, K+, and Cl- 
through the membrane; thus mediating cell-cell communication and cellular excitability. 
LGICs are the fundamental signaling molecules in neurons, and are consist of three 
domains: the extracellular amino-terminal domain containing the ligand-binding site, the 
hydrophobic transmembrane-domain containing the ion channel, and the intracellular 
domain (Figure 1.1). LGICs are divided into three superfamilies based on their structure 
and function: ATP-gated channels, ionotropic glutamate receptors, and cysteine-loop 
(cys-loop) receptors (2).
The cys-loop receptors have a disulfide bond between two cysteine residues (13 
amino acids apart) in the N-terminal extracellular domain. Mutation of these cysteines 
or elimination of disulfide bond produces a non-functional protein. Cys-loop receptors 
are composed of five protein subunits that form a pentameric arrangement around a 
central pore. Individual subunits have three domains: a) a large extracellular amino- 
terminal domain which is contains mostly p-sheets. This domain contains the N-and-C 
terminal residues, a small M2-M3 region, and a ligand-biding site. The binding sites are
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Figure 1.1: Ligand-gated Ion Channel, Nicotinic Acetylcholine Receptor Structure. Ribbon structure 
shows different domains of a ligand-gated ion channel. Protein Data Bank (PDB) file 2BG9.
composed of six loops of amino acids referred to as A-F, and each subunit contributes 
three loops on each of its two interfaces. The neurotransmitters bind at the interface 
between subunits in the extracellular, N-terminal, ligand binding domain; b) four 
transmembrane regions (M1-M4) of a-helices which form the ion channel (ion pore), and 
are involved in ion-selectivity. The pore is primarily formed by the M2 helices; and c) an 
intracellular domain of a-helices that contains a large M3-M4 region. The intracellular 
(or cytoplasmic) domain interacts with the interior of the cell, relaying the signal which 
can depolarize or hyperpolarize the cell (Figure 1.2).
In cys-loop receptors, the ion channels open in response to binding of a specific 
ligand molecule to the extracellular domain of the receptor protein (3,4). Ligand binding 
causes a conformational change in the structure of the channel protein that leads to the 
opening of the ion pore, and subsequent ion flux across membrane and into or out of
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ions
Figure 1.2: Schematic of Cys-loop LGIC. A: Side view of a single subunit. B,C, D: Side and top views 
of the pentamer. Arrows in C-and-D indicate potential ligand binding sites.
the cell. Ion flux is passive; thus Ions pass through channels down their electrochemical 
gradient without the input of metabolic energy (e.g. ATP or active transport 
mechanisms). The flow of charged ions represents an electrical current that changes 
the voltage across the membrane, which can be transmitted rapidly over long distances 
and trigger downstream effects (1). Channel activity is terminated when the channel 
closes or when it enters a desensitized (non-conducting) state (5).
Members of the cys-loop LGIC are divided into four different subfamily of 
receptors based on their endogenous agonist/ligand: nicotinic acetylcholine (nACh), 
glycine, Y-aminobutyric acid (GABA), and 5-hydroxytryptamine type 3 (5-HT3) (1).
These receptors can be further subdivided with respect to the type of ion they conduct: 
GABA and glycine are anion-selective channels that conduct Cl- ions, thus producing 
neural inhibition, and are commonly referred to as inhibitory channels; whereas nACh 
and 5-HT3 receptors are cation-selective channels that conduct Na+, Ca2+ and K+ ions, 
producing neural excitation and are referred to as excitatory channels (6).
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The 5-HT3 receptors differ in structure and mechanism from the other serotonin 
receptor subtypes (types 1, 2 and 4), which are all G-protein-coupled receptors (7-10). 
The 5-HT3 receptors are expressed in the nervous system in regions involved in the 
cognition, anxiety, seizure (11), addiction, GI motility (12), emesis and nausea (13).
The pharmacology of the 5-HT3 receptors varies among species, and evidence for 
different subtypes within a single species was first noted in 1993 by Bonhaus et al. (14). 
Recent studies show that different 5-HT3 receptor subtypes (3A, 3B) are transcribed 
and located in different areas of the nervous system (8). Information regarding receptor 
heterogeneity and its localization is very important to understand involvement of the 5- 
HT3 receptor in normal physiology of the nervous system, as well as its role in different 
diseases (15). To determine subunit composition of individual receptors requires 
ligands that have the ability to discriminate between different subtypes of the 5-HT3 
receptor (16).
The 5-HT3 receptors are most closely related by homology to the nACh receptor, 
and site-directed mutagenesis studies have focused on regions of the 5-HT3 receptor 
amino terminal homologous to the nACh receptor binding loops A-F (17). Mutagenesis 
studies on the murine (mouse) 5-HT3 receptor have identified a number of amino acid 
residues that are important for binding of agonists and competitive antagonists to the 5- 
HT3 receptor (18,19), and key amino acids have been identified in loops-B (20), loop-C 
(18) and loop-E (21). The 5-HT3 receptor is discussed in more detail in Chapter 4.
1.2 Health and Diseases Related to Cys-loop LGICs
Cys-loop receptors are involved in a wide range of physiological processes as 
they mediate both excitatory and inhibitory neurotransmission (22). These receptors 
are crucial to the function of the peripheral and central nervous systems, and have been 
implicated in learning and memory, fluid balance, appetite control, regulation of blood 
flow, and pain (22). The malfunction of cys-loop LGICs is linked to various diseases 
and disorders such as muscular dystrophies (23), central neurological disorders (e.g. 
autism and attention deficit hyperactivity) (24,25), neurodegenerative diseases (e.g. 
Alzheimer’s, Parkinson’s) (26-29), neuropsychiatric disorders (e.g. anxiety, epilepsy, 
schizophrenia, depression) (30,31), and nicotine, drug and alcohol addiction (32,33).
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Clearly, cys-loop receptors cover a wide spectrum of functions, ranging from 
muscle contraction to cognitive functions, which in turn makes them important drug 
targets for the treatment of nervous system disorders and diseases. Therefore, drug 
discovery strategies require an in-depth understanding of the ligand binding sites, and 
structure-function relationships between the receptor and ligand/drug.
1.3 The Drug Discovery and Development Process
Developing a new drug from concept to therapeutic agent is a very complex 
process (34,35), which includes drug discovery and screening, pre-clinical trials using 
non-human subjects (work on animals such as rats), toxicity studies, clinical trials using 
human subjects, and approval by Food and Drug Administration (FDA). This process 
can take an average of 15 years and cost in excess of US$1 billion per new 
pharmaceutical drug (Figure 1.3) (34).
The first step of developing a pharmaceutical drug is drug discovery and 
screening (pharmacodynamics). The process of drug discovery begins by targeting a 
medical condition or disease that lacks a suitable therapeutic intervention. The initial 
research often occurs in academia, and generates data to develop a hypothesis that the 
activation or inhibition of a pathway or receptor protein will have therapeutic effect on 
the condition or disease. Once the target (e.g. pathway, gene or receptor protein) is 
identified, an intensive search to find or produce a drug begins (36,37). New drugs are 
typically identified in ‘natural products’ or produced using ‘combinatorial chemistry’ (38).
Natural products are organic compounds from marine and terrestrial organisms, 
including terrestrial plants, microorganisms, vertebrates and invertebrates, that may 
have played an important role in preventing and treating human diseases for thousands 
of years, or may be the result of extensive screening of natural materials (39,40).
These natural products can serve as compounds of interest both in their natural state 
and/or through synthetic modifications (41,42). Combinatorial chemistry is the method 
of synthesizing many different substances at the same time (43). The result is 
production of thousands of new molecules / compounds, called ‘libraries’, which have to
5
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Figure 1.3: The Drug Development Process and Timeline. Drug discovery is the first stage of drug 
development process where thousands of potential drug candidates are tested and screened. In the 
second stage, preclinical trial, the ‘lead compounds’ are tested on animals and screened further. Clinical 
trial is the third stage where the drug is tested on humans. Information from all studies is received by 
FDA, and if satisfied, product license is issued and the drug is marketed. Information to develop the 
figure was obtained from: https://www.fda.gov/drugs/developmentapprovalprocess/
be screened and identified (44,45).
Potential drug candidates, whether discovered in academic or pharmaceutical / 
biotech research labs, are rigorously tested and screened for their interaction with the 
target and for off target interactions that may produce side effects or toxicity. Many drug 
candidates fail at this stage since they do not work, do not interact with the target, are 
not highly selective or are not safe. After careful review of the results (46,47), ‘lead 
compounds’ are chosen for early testing or ‘pre-clinical’ trials on animals.
Tufts Center for the Study of Drug Development (csdd.tufts.edu) has published 
numerous studies estimating the cost of developing new pharmaceutical drugs. In 
2001, the cost was estimated at US$802 million; in 2010, the research and development
3-20 years 
(avg. 7 yrs.)
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cost of each new drug was estimated about US$1.8 billion; in 2014, the estimated cost 
of developing a prescription drug that gains market approval was estimated at US$2.6 
billion (48) ; and in 2016, the cost was found to have averaged US$2.9 billion per new 
pharmaceutical drug (49,50).
Drug discovery and screening is the area of research in the drug development 
process that takes the most amounts of time and money. The timeframe can range 
from 3-20 years, and costs can range between several million to tens of millions of 
dollars (51). The drug discovery process is often a difficult, lengthy, expensive, and 
inefficient process despite of many advances in technology. In addition, an incomplete 
knowledge of the specific receptor type and subtype involved in different diseases and 
disorders presents many challenges in developing therapeutic approaches since it 
requires receptor-selective or subtype-selective drugs.
The process of drug discovery starts with thousands of compounds as potential 
drug candidates; however, only a small number of compounds look promising and 
undergo further study after early testing (52). On average, only 5 in every 5,000 
compounds that make it as the ‘lead compound’ to the ‘pre-clinical trial’ stage becomes 
an approved compound/drug to be tested on humans (Figure 1.3), and only 1 of those 5 
drugs that progress to human ‘clinical trials’ is approved by the FDA as a marketable 
drug (53). Clearly, developing subtype-selective drugs is hindered by the high cost, as 
well as inability to rapidly evaluate candidate compounds on multiple receptor subtypes. 
Therefore, the length of time required for drug discovery and screening, as well as its 
associated expenses to develop a marketable drug, calls for new approaches and 
technologies -- approaches that enable the researchers to either discover or produce 
new drugs for many receptor subtypes quickly, efficiently and economically.
1.4 Basic Steps and Different Methods of Drug Discovery
Following the identification of potential drug candidates, vigorous testing and 
screening of these compounds are needed to study their interaction with the target and 
identify potential drug candidates. A drug discovery method which is widely used in 
both academic laboratories and in the pharmaceutical industry is called high-throughput 
drug screening (HTDS). HTDS uses automation (robots, liquid handling devices,
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sensitive detectors, and data processing/control software) to quickly screen the entire 
libraries of chemicals against the target (54,55). It allows researchers to rapidly screen 
libraries containing millions of compounds, with molecular weight of <300 Da and 
identify the molecules that interact with the drug target to select lead compounds (56). 
This information provides a starting point for drug design and/or understanding the 
interaction and/or role of a particular biochemical process. Another important function 
of HTDS is to show how selective the compounds are for the chosen target since the 
ultimate goal is to find a molecule which will only interact with the chosen target, and no 
other related targets.
It should be noted that HTDS is an expensive method, and requires highly 
specialized and expensive instrumentations. Therefore, other approaches to drug 
discovery have been pursued to screen smaller libraries, namely fragment-based drug 
discovery (57,58) and protein-directed dynamic combinatorial chemistry (59,60). These 
methods use libraries that are composed of a few thousand compounds with molecular 
weight HTDS of around 200 Da. The ligands used in the process are small and bind to 
the target with a weak binding affinity in millimolar range (HTDS requires nanomolar 
binding affinity). The promising ligand-target complexes are then studied through X-ray 
crystallography (61,62) and suggested modification(s) are generated and applied to 
produce lead compounds with a higher affinity for the target (63-65). When compared 
to HTDS, these methods have the advantage of efficient screening as well as 
generating a library that covers a large chemical space.
Another important drug discovery method is de novo drug design which utilizes 
computer software, and involves the design of molecules that are complementary in 
charge and shape to the binding site of target with which they interact and bind to.
There can be different approaches to this method, for example, ‘virtual high throughput 
screening’ (45,47,66), where screening of potential drugs are accomplished using 
computer-generated models of the target and docking of virtual libraries to a drug target. 
Another approach, namely ‘computer-aided drug design’ (67,68), uses virtual screening 
of libraries of small molecules to identify compounds whose structure are most likely to 
bind and interact with a target. Once the lead compounds are identified, molecular 
modeling (69) and molecular dynamics stimulations (70,71) are used to improve the
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potency, selectivity and physiochemical properties of the potential lead molecules or 
drugs.
1.4.1 Traditional Approaches to HTDS
Scientists in academic labs and small biotechnology companies have traditionally 
used high-throughput screening method of drug discovery in receptor-binding assays 
and functional assays. These are cell-based assays that investigate the effect of a 
given treatment (e.g. drug) on living cells. Receptor-binding assays (RBAs) are typically 
used to study membrane proteins/receptors (72). RBAs are competitive inhibition 
assays using a known radiolabeled drug (derived from chemical or natural product 
libraries), to examine the interaction of a drug/ligand with receptor/target. RBAs 
typically use filter-based separation methods to obtain data for bound versus free 
drug/ligand fractions and obtain quantitative binding parameters such as Km and Bmax, 
to determine minimal effective drug concentrations (73). RBAs are not only used for 
identification of lead compounds, but also for characterization of drug candidates (e.g. 
drug stability, mechanism of action, potency and purity). Although RBA has been 
developed for HTDS, it is an expensive method which requires living cells and 
radioactive materials (72-74).
A second approach to drug screening employs functional assays. Functional 
assays (e.g. automated oocytes and patch clamp), are electrophysiology methods that 
are used to study the functional activity of a target. These assays involve biological 
organisms and the data reflect the effect of receptor activation or its block rather than 
direct measures of receptor interaction as with RBAs. This causes the system 
intrinsically more complex in composition or behavior, or both, making the reading and 
interpretation of the assay(s) more difficult (75,76). Functional assays are expensive to 
perform, and are considered medium HTDS, since experiments are intrinsically slower 
to perform as they require live cells and membrane preparations. Functional assays do 
provide information not provided by receptor assays, but would ideally be performed 
once an appropriate HTDS assay has identified a smaller subset of the library as a 
viable option (76).
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1.4.2 Modern Approaches to HTDS: Biosensors
In addition to traditional approaches to HTDS, there are more recent innovations 
in high-throughput methods and instruments that have become powerful analytical tools 
because they can measure the activity and binding of very diverse classes of drug 
targets. These are called ‘sensor surfaces or biosensors’. Biosensors are analytical 
devices composed of an immobilized biological material (e.g. antibody, cells) which can 
specifically interact with an analyte (e.g. drug) to produce signals (e.g. electrical, 
physical, chemical, etc.) that can be measured. Examples of biosensors are: surface 
plasmon resonance (77), microcantilever (78), and scintillation proximity assay (79).
Surface plasmon resonance (SPR) is a rapid, non-radioactive, and chip-based 
technology developed by Biacore Inc. (www.biacore.com), which relies on plasmon 
resonance (77,80). Plasmon resonance refers to the excitation of surface plasmon by 
light. Surface plasmons are electromagnetic waves that propagate along a metal 
surface, and molecules binding to the surface interact with the waves, altering its 
properties. The SPR is composed of as sensor chip, a flow cell or channel, a light 
source, a prism, and a detector. The sensor chip is a gold-coated glass chip, which is 
sandwiched between a flow channel (containing buffer and ligand solution), and a glass 
prism. The chip is coated with coupling reagents that attach the desired protein or small 
molecules to the chip surface. As ligands in solution buffer flow through the channels, 
they bind to the molecules on the chip surface. Protein and ligand binding results in 
alteration of chip surface properties, which lead to changes in surface plasmon waves. 
The end result is a change in the angle of reflection of light. The SPR Biacore 
instrument monitors and measures this angle and its changes, which correspond to the 
ligand binding to the protein or small molecule on the gold surface of the chip.
Therefore, SPR measures changes in molecular weight over time. For the Biacore SPR 
instruments, the detection limit for ligands binding to the chip is about 180 KD, thus in 
general, the lower molecular weight molecule is attached to the chip and the higher 
molecular weight molecule is placed in the flow channel with buffer (Figure 1.4).
Microcantilevers (MCs) are chip-based sensor devices that can detect changes 
in cantilever bending or vibrational frequency (78,81). In MC, the biosensor protein is
10
Figure 1.4: Schematic of Surface Plasmon Resonance. The properties of the gold surface changes as 
molecules bind to the chip surface, leading to changes in surface plasmon waves. This causes a change 
in the angle of reflection of light which is detected and measured in resonance units (RU). Picture 
adapted from Biacore TN1 handbook.
bound to a chip on one side of the cantilever, and the ligand is run over the chip. The 
biosensor protein and ligand can have different forms of molecular interaction such as 
electrostatic attraction, repulsion, conformational change, etc., which results in the 
cantilever surface expanding or contracting on the side containing the receptor in 
response to ligand binding. The expansion or contraction of only one side causes the 
cantilever to deflect and bend up or down. This deflection is detected as a change in 
position of the reflected light hitting the detector which can be measured using optical 
techniques or piezoelectric effects. The information from the detector is sent to a 
computer for analysis (Figure 1.5).
Scintillation proximity assay (SPA) is a bead-based technology used to study 
radioligand binding (79,82). SPA utilizes microscopic size SPA beads coated with a 
scintillant. Protein of interest is typically bound to the bead surface and then exposed to 
a radioligand. The scintillant emits light when it is stimulated by the interaction of 
radiolabeled molecules and their binding to the surface of the bead. The SPA technique 
relies on the process of radioactive decay during which the radioligand releases a beta 
particle. The beta particle, when close to the beads, causes the scintillant coating of the 
bead to emit photon/light. This signal is detected by scintillation counter and analyzed
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Figure 1.5: Schematic of the Microcantilever Mechanism. At left, the protein is bound to one side of 
the microcantilever. At right, the ligand binds to the protein and causes the surface to expand (as shown) 
or contract on one side only, resulting in bending which is detected optically or piezoelectrically. 
Information obtained from our collaborator, Dr. Hai-Feng (81).
using GraphPad Prism software. Incorporation of scintillant into the bead eliminates the 
filtration step since only radioligand bound at close proximity to the bead can excite the 
scintillant, and trigger the bead to emit light (Figure 1.6).
The biosensors mentioned above, namely, surface plasmon resonance (SPR), 
microcantilever (MC), and scintillation proximity assay (SPA) clearly have many 
advantages and at the same time their own limitations. SPR is a label-free binding 
assay that can detect binding of non-labeled compounds, as well as non-competitive 
ligands, which makes it a good candidate for screening libraries of non-labelled 
compounds and natural products. In addition, SPR can provide association and 
dissociation constants (on-and-off rates). However, this method is not designed to 
study low molecular weight compounds since it relies on molecular weight detection; 
therefore, to investigate any compound below 120 KD requires another type of 
biosensor (80).
MC is a label-free detection method which is low-cost, and is capable of rapid 
screening of multiple receptors and mass production. MC has a high sensitivity level 
and can differentiate between agonist versus antagonist binding (81). This biosensor is 
relatively new and requires further study, adjustment and tuning.
SPA is a high-throughput binding assay that requires a small quantity of protein 
and is able to evaluate binding of competitive ligands. This is a low-cost assay without 
any molecular weight limitations for compounds which is ideal for working with and 
detecting small molecules. SPA differs from the traditional receptor-binding assay as it
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Figure 1.6: Schematic of the Scintillation Proximity Assay. At left, the radioligand emits B-particles 
and when it is bound and in close proximity to the bead, it causes the scintillant coating of the bead to 
emit a photon, which is detected by the counter. At right, unbound radioligand is not close to the bead 
and does not excite the scintillant. Picture adapted from SPA handbook (GE/Amersham Biosciences).
does not require a separation of free and bound radioligand (79). Therefore, it 
represents a convenient method to assay a wide range of molecular interactions in a 
homogenous system. In addition, elimination of the filtration step permits automation 
and high-throughput assay development. SPA has the disadvantage of requiring the 
use of radioligand for direct determination of Kd although it can be used to determine an 
indirect inhibition constant (Ki) for non-labeled compounds when used with a selective 
radioligand. SPA cannot be used to detect binding of non-competitive ligands. SPA 
technology does provide a rapid and sensitive method which is routinely used for drug 
screening where ligand-binding affinity and high-throughput is required.
The ultimate goal of any biosensor technology is to develop a platform which is 
able to detect and identify different molecules with high sensitivity and accuracy at a 
reasonable price. And the ideal system for the drug discovery is one in which the 
biosensor can use <1 mg of drug and identify every receptor that it binds. Therefore, in 
order to perform high-throughput drug screening, a ‘specific sensor protein’ is needed 
which can rapidly and reversibly detect binding of potential lead compounds. The 
current problem with all the biosensors is the lack of this appropriate ‘specific sensor 
protein.’ Biosensor applications typically require pure protein capable of being 
immobilized intact on a sensor bead or surface. This is a particularly large problem with 
the ubiquitous membrane-bound proteins as they are challenging to purify, and when
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purified in lipid or detergent, they are difficult to immobilize or may be inactive (1).
Ideally, a receptor would be solubilized, purified and covalently attached to a sensor 
surface, then used over and over again to screen large numbers of compounds.
1.5 Development of Sensor Proteins for Small Molecules
Studying the mechanism by which proteins fold into their correct three­
dimensional structure, as well as their interaction with other proteins or small molecules 
has been the focus of intense research as it is the segue to developing particular or 
specific sensor proteins. Here, we will focus on three approaches that address 
development of sensor proteins for small molecules, namely: periplasmic proteins, intact 
receptors in synthetic membranes, and human proteins without transmembrane 
components.
1.5.1 Periplasmic Proteins
Periplasmic proteins are present in the periplasm of bacteria. The periplasm is a 
gel-like fluid in the space between outer membrane and inner, or cytoplasmic, 
membrane in both gram-positive and gram-negative bacteria (83,84). The periplasm 
contains a number of proteins (e.g. proteases, nucleases, phosphatases, etc.) that carry 
out different functions. For example, some periplasmic proteins are involved in folding, 
electron transport, substrate hydrolysis, and degradation of large molecules (e.g. large 
proteins, nucleic acid, etc.) into smaller and transportable sizes (85) .
Other type of periplasmic proteins, called periplasmic-binding proteins (PBPs), 
are secreted by bacteria, and are involved in nutrient binding and transport (86). PBPs 
bind to different molecules (e.g. sugars, ions, amino acids, etc.) in the environment, and 
transport them into the periplasm. Once in the periplasm, PBPs bind to cytoplasmic 
membrane-bound proteins and release their bound molecule. The nutrient molecule is 
then transported into the cytoplasm, and PBP is secreted back into the bacterial 
surroundings (87). Clearly, a number of proteins of interest in biotechnology are 
present in the bacterial periplasm, such as PBP. The PBP has been recognized as a 
biosensor molecule/protein due to its small size, and its ability to recognize and 
transport different molecules into the periplasm by coupling with them (88).
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Advantages of this approach are: a) proteins are widely available, and b) proteins 
have broad ligand specificity. In addition, some modeling has been done that shows 
proteins can be mutated for different ligand selectivity (89). The main disadvantage of 
this approach is use of bacterial protein. Based on current receptor modeling, it is 
assumed that the bacterial proteins can be mutated for specific ligand selectivity or 
respond to certain drugs; however, they may not respond to unknown drugs the same 
as a human receptor since the modeling is based on bacterial proteins.
1.5.2 Intact Receptors in a Synthetic Membrane
Another technology for drug discovery is use of intact receptors in a synthetic 
membrane. In this method, artificial or synthetic membranes are used to model the 
properties of native membrane, and provide an isolation or separation environment 
(90,91). The intact receptor is prepared by using a detergent purification system, and it 
is then inserted into the artificial membrane bilayer. The main advantage of this method 
is the ability to use human proteins, thus the response to certain drugs should be similar 
to human receptors. However, this technology has many disadvantages in regard to 
protein production, insertion and stability. For instance, it is very difficult to prepare 
intact receptor proteins as proteins are known to lose their structure and/or activity when 
purified with detergent (1). In addition, attempting to insert a receptor protein into the 
synthetic membrane, without losing protein activity and stability, introduces its own 
challenges. Furthermore, producing a synthetic lipid membrane system with all its 
components and characteristics is a daunting task that has not yet been achieved since 
membranes adapt their composition in response to environmental cues, and cells use 
lipid remodeling to carry out specific tasks (e.g. signaling, division) or respond to their 
environment and maintain membrane homeostasis (1).
1.5.3 Human Proteins without Transmembrane Components
A new approach to address development of sensor proteins for small molecules 
is use of human proteins without transmembrane (TM) components (92). Cell 
membranes are composed of lipid bilayers which provide the structure of the 
membrane. A number of proteins are inserted into this hydrophobic environment that
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allow for many of the interactions that occur within and between cells, such as cell 
signaling, division, movement of specific molecules into and out of the membrane, etc. 
(92).
The two main categories of membrane proteins are integral proteins and 
peripheral proteins. Peripheral proteins are temporarily attached to integral proteins or 
to the lipid bilayer by hydrophobic, electrostatic, and other non-covalent interactions. 
This type of interaction can be disrupted by the change in pH. On the other hand, 
integral membrane proteins are permanently bound to the membrane. They are 
classified as integral monotopic proteins if they are attached to only one side of the 
membrane, and transmembrane proteins if they span across the entire lipid bilayer or 
membrane (1). The transmembrane proteins are composed of one or more segments 
that are permanently embedded within the lipid bilayer, and their amino acid residues 
contain hydrophobic side chains that interact with the hydrophobic interior of 
phospholipid bilayer. These stretches of approximately 25 hydrophobic residues that 
pass across the membrane are known as transmembrane domains (TMDs). TMDs are 
not only involved in anchoring the integral proteins to the membrane, but also in forming 
ion channels, enzymatic sites, or transporters (6,22).
Transmembrane proteins account for the majority of membrane proteins, and 
they can only be dissociated from the membrane using detergent, non-polar solvents, 
and denaturing agents (1). Therefore, removing transmembrane proteins from their 
native surrounding, as well as removing the transmembrane domains may lead to 
destabilization of the protein, which is the main disadvantage and challenge of 
developing human protein analogs using removal of the transmembrane component 
approach (1). However, there are many advantages to this method; for example, most 
ligands bind to the extracellular domain of a protein, and the majority of proteins have a 
large extracellular domain (e.g. LGIC). Therefore, there is an excellent possibility that 
this approach would work. In addition, these proteins can be produced, purified and 
characterized easily, and due to their stability, they can also be stored, shipped, and 
manufactured. Furthermore, this approach uses the binding domain of a human protein 
which means its response to unknown drugs would be the same as a human receptor 
(92).
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1.6 Approaches of Developing Soluble Binding Domains
Drug screening approaches, particularly chip-based systems used in HTDS, are 
greatly facilitated by the use of soluble proteins. Unfortunately, this is often not a viable 
option for receptor proteins such as ligand-gated ion channel (LGIC) receptors that are 
principal targets for a large class of therapeutic drugs. A solution to this problem would 
be to engineer the desired protein(s) using a soluble homolog of the receptor as a lead 
molecule. For LGICs, nature has provided an ideal candidate in the acetylcholine- 
binding protein (AChBP) (93,94).
The AChBP is a water-soluble protein secreted by glial cells in the central 
nervous system of the fresh water snail, Lymnaea stagnalis, where it specifically binds 
to acetylcholine (ACh) and inactivates it at the synapse (95,96). Other AChBP proteins 
have been discovered in other snail species as well (97,98). The AChBPs are 
structurally homologous to the amino terminal domain of LGIC receptors with a 
relatively high sequence identity (15-30%) in the extracellular ligand-binding domain
(20.99). Like the nACh receptor, the AChBP has a tertiary structure consisting of five 
identical subunits (210 amino acids each), and assembles in a homo-pentameric form
(93.99). Unlike the nACh receptor and other LGICs, the AChBPs lack the 
transmembrane domain, making them soluble homologs rather than integral membrane 
proteins. Since they are soluble proteins, crystal structures of the AChBPs have been 
resolved to 1.8A° (100,101). These crystal structures have been used extensively in 
developing homology models of the N-terminal, ligand-binding domain of cys-loop LGIC 
receptors (nAChR, GABA, glycine, and 5-HT3) (93,99). More recent structures of the 
LGICs themselves have corroborated the structural similarity of the AChBPs and the 
validity of these homology models (102,103). In addition, site-directed mutagenesis and 
affinity labeling experiments on the AChBP have shown conservation of residues 
involved in the ligand-binding site and receptor-binding function of LGIC in general, and 
nicotinic receptors in particular (101,104). For example, the AChBP binds to the 
agonists and competitive antagonists of the nicotinic ACh receptor (e.g. nicotine, ACh, 
bungarotoxin, epibatidine, and tubocurarine), and the crystal structure of these complex 
binding sites have provided insight into the ligand-binding domain of nicotinic ACh 
receptors (101,105).
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The application of the AChBPs as cys-loop LGIC receptor models is further 
supported by experiments showing that the Lymnaea stagnalis AChBP can be 
functionally coupled to the transmembrane region of a 5-HT3 serotonin receptor, and 
trigger opening of the ion channel (106). Clearly, similarities between the AChBPs and 
LGICs binding domains make them ideal candidates for the study and modeling of cys- 
loop LGIC receptors and their interactions with various ligands and drugs.
As a model system, an AChBP needs to be modified so it can be placed on a 
biosensor surface and used as a biosensor molecule capable of detecting different 
classes of ligands. There are two different approaches for modification of an AChBP 
and development of a soluble binding domain: mutagenesis and chimera construction. 
Chimera experiments executed by several labs have encountered numerous problems, 
and in general have not yet been very successful (107,108). However, there have been 
some results when mutagenesis was used in conjunction with chimera construction, 
where the ligand was able to recognize and bind to the chimera if the AChBP residues 
were also mutated to their counterpart in the cys-loop LGIC receptor (106). On the 
other hand, mutagenesis introduces its own problems, namely the fact that the AChBPs 
are snail proteins. Therefore, data only provide information about the snail protein, and 
any information about the human protein could only be inferred. This is insufficient for 
drug screening where a modified protein would be required to mimic the endogenous 
receptor protein binding site with a high degree of fidelity.
Taken together, it appears that although the AChBPs are good models of cys- 
loop LGIC receptors, more information about similarities and differences between the 
AChBP and LGIC receptors are needed before the AChBP can be modified and used 
as a biosensor molecule. One of the best ways to investigate similarities and 
differences is through mutagenesis where a binding site that is similar between the 
AChBP and LGIC receptor superfamily is developed. This task could potentially be 
accomplished through systematic site-directed mutagenesis designed to alter and hone 
the selectivity of an AChBP to favor specific LGIC receptor ligands.
The end result of this work will be the development or engineering of a soluble 
biosensor molecule similar to a human receptor protein that can be used in biosensor 
applications (e.g. SPR, MC, SPA) including high-throughput screening of small
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molecules (e.g. drugs). An engineered soluble receptor analog suitable for biosensor 
use would allow screening of a wide range of natural products and synthetic drugs in a 
much shorter period of time. As the cost of drug discovery is about 1/3 of the cost of 
developing a drug (https://www.fda.gov/drugs/developmentapprovalprocess/ ), this 
would represent a large cost savings. Such proteins would also find important uses in 
detection of bioweapons or bedside drug screenings as these receptors are important 
receptors for toxic compounds as well (109).
1.7 Hypothesis and Specific Aim
The overarching goal of this Dissertation is to explore the AChBP as a potential 
biosensor molecule, and use it as a template for development of a soluble binding 
protein suitable for high-throughput biosensor devices. The target receptor protein is 
the serotonin type 3 (5-HT3) receptor, important in central nervous system disorders 
and the anti-emetic class of therapeutic agents.
We hypothesize that the AChBP can be modified by site-directed mutagenesis to 
mimic the ligand selectivity and specificity of the 5-HT3 serotonin receptor. The specific 
aim of this Dissertation is to engineer a soluble serotonin-binding protein using the 
AChBP, which will mimic the specificity of native 5-HT3 serotonin protein. This will be 
approached in a sequential manner as follows:
1) Develop stable cell lines and expression of the Lymnaea AChBP and 
evaluate its pharmacology using SPA (Chapter 3).
2) Create mutations of the AChBP consistent with the 5-HT3 receptor ligand 
interactions designed to improve interactions of the AChBP with serotonin 
ligands (Chapter 4).
3) Create double mutations to determine if the selectivity for serotonin ligands 
can be enhanced (Chapter 4).
4) Using the data from 2-and-3 above, produce a new model and suggest new 
mutations to further enhance selectivity for serotonin ligands (Chapter 5).
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Chapter 2: Materials and Methods
2.1 Construction of the AChBP
The AChBP used in this project was custom synthesized by GeneArt Inc. 
(Germany), using an AChBP cDNA sequence identical to the molluscan snail Lymnaea 
stagnalis (Figure 3.3, Source: http://www.uniprot.org/uniprot/P58154 ). The following 
modifications to the AChBP sequence were made to provide for ease of purification and 
attachment to sensor surfaces:
a) An N-terminal FLAG tag was added by insertion of the synthetic AChBP gene 
into a p3xFLAG-CMV-9 expression vector (Sigma, Figure 3.2). The p3-Flag 
epitope tag is used with an anti-FLAG antibody for detection, characterization, 
and immobilization of the protein.
b) A C-terminal 6X His tag was added to the vector to facilitate rapid protein 
purification. This tag is used for immobilization of the protein on nickel and 
copper-containing surfaces such as the SPA beads.
c) A pre-protrypsin leader peptide preceding the FLAG tag was added for ease of 
protein recovery from cell culture. This allows for secretion of the AChBP into the 
extracellular medium surrounding the cell culture.
d) The expression vector also contains ampicillin-resistant and G418-resistant 
genes for clonal selection of stable transfectants in both bacterial and 
mammalian cell lines (HEK-293 cell lines). This provides rapid development of 
sable cell lines for protein production.
2.2 Amplification of the AChBP
XL-1 blue supercompetent E.Coli cells were transformed with the AChBP/ 
p3xFLAG-CMV-9 DNA using standard protocol and reagents (Stratagene). DNA was 
purified using Mini-prep and Maxi-prep (Qiagen), and the presence of the insert (vector 
DNA) was verified by restriction digest and agarose gel electrophoresis. The process of 
transformation and verification required over one week time for a single DNA sample 
(for the AChBP and each mutant DNA afterward). The DNA was sequenced by
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commercial sequencing (Sequetech Corp, Mountain View,
CA, http://datasytem. sequetech.com).
2.3 Stable Expression of the AChBP
The AChBP/p3xFLAG-CMV-9 plasmid DNA prepared by Maxi-prep, and verified 
by Sequetech, was transfected into HEK-293 cells (Human embryonic kidney cells, 
ATCC), to develop stably transfected cell lines that secrete an AChBP containing an N- 
terminal FLAG epitope tag and a C-terminal poly-His tag into the extracellular medium 
surrounding the growing HEK-293 cell culture.
Prior to transfection, a kill curve (dose response curve) for HEK-293 cells was 
established using antibiotic G418 (BD Biosciences). Untransfected HEK-293 cells were 
plated at a 106 cells/cm2 cell density and placed in DMEM media (ATCC) supplemented 
with 10% Fetal Bovine Serum (Invitrogen), 2% Penicillin/Streptomycin (Invitrogen), and 
G418 antibiotic (Sigma-Aldrich) at varying concentrations. Cells were incubated at 37 
°C in a humidified atmosphere of 5% CO2 in a growth chamber / CO2 incubator. The 
optimal concentration of an antibiotic is considered to be that which results in 90% cell 
death (when cells become round and fail to adhere to the dish) in one week, and 100% 
cell death within two weeks. Based on these criterions, the optimal G418 concentration 
was determined to be 0.4 mg/ml. This concentration of the G418 antibiotic was 
sufficient to kill all HEK-293 cells that did not contain p3xFLAG-CMV-9 vector.
Stable transfections were performed using the SuperFect reagent kit and 
protocol (Qiagen). Cells were maintained in DMEM media (ATCC) supplemented with 
10% Fetal Bovine Serum (Invitrogen), and 2% Penicillin/Streptomycin (Invitrogen) for 48 
hours after transfections. Medium was then replaced with fresh supplemented DMEM 
and 0.4 mg/ml G418 antibiotic. Cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO2 in a Growth chamber / CO2 incubator. Cells recovered very 
slowly, and over one month of incubation and change of medium (twice a week) was 
required before sufficient cells were obtained to allow splitting of cells and its 
propagation (the same applied for each subsequent mutant DNA).
Cells were split into new flasks when 90-95% confluent (an average of once a 
week). The culture medium was removed and cells were washed with 10-ml of warm
22
Dulbecco’s phosphate buffered saline (ATCC) at 37 °C in a water bath, and then re­
suspended in 10-ml of fresh DMEM (plus 10% Fetal Bovine Serum, 2% 
Penicillin/Streptomycin, and 0.4 mg/ml G418 antibiotic) by repeated up-and-down 
pipetting. Typically, 0.5-ml of the cell suspension was transferred to a new flask and 
diluted with 24.5 of fresh warm DMEM growth media. After several passes, the 
surviving cells were determined to contain a stable copy of the AChBP/p3xFLAG-CMV- 
9 plasmid. Stable cell lines actively secrete an AChBP containing a C-terminal poly-His 
tag and an N-terminal FLAG epitope tag into the culture medium.
The process of cell splitting and growth of stable cell lines required an average of 
one month (for the AChBP and each mutant DNA afterward) before stable cells could 
be transferred to large flasks suitable for large scale protein production. Once cells 
were split and transferred to large cell culture dishes (VWR) that could hold 100-120 ml 
of media, the cell culture media was collected at 90-95% cell confluency (an average of 
twice a week), for protein purification.
2.4 Purification of the AChBP
Culture medium from flasks containing the AChBP/HEK-293 cells was collected 
every 2-3 days. The AChBP was purified from the cell culture medium using a 
Dynamax machine with Nickel-EDTA His-Select Columns (Sigma) with the following 
modifications to Sigma’s protocol: a) addition of salts to the collected medium at the 
concentrations of 50mM sodium phosphate (monobasic, Na2HPO4), 0.3M sodium 
chloride (NaCl), and 10mM imidazole; b) adjustment of medium pH to 8.0 using 1M 
sodium hydroxide (NaOH), and; c) filtration of medium through 0.2-^m cellulose acetate 
filters. Addition of imidazole served to decrease non-specific protein binding to the 
affinity column resulting in a highly pure final product, and NaCl was used to increase 
the ionic strength of the solution.
Purification is based on the binding of a 6X His tag incorporated into the AChBP 
to the highly selective His-Select affinity resin. Therefore, the Nickel-EDTA His-Select 
Columns were equilibrated before and after the protein purification with 10-ml/column of 
a media-free equilibration buffer, 50mM Na2HPO4, 0.3M NaCl, 10mM imidazole, and 
adjusted with sodium hydroxide to pH of 8.0. Adjusted culture medium was placed on
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ice for the duration of the protein purification process, and then loaded onto equilibrated 
Nickel-EDTA His-Select Columns at a flow rate of 4ml/min for protein purification at 
room temperature.
The bound protein was eluted with elution buffer (50mM Na2HPO4, 0.3M NaCl, 
250mM imidazole) with pH of 8.0. This buffer has a higher concentration of imidazole 
since imidazole acts as a competitor for binding to the AChBP. Elution was performed 
in the following manner: pre-wash (0:00-1:00 minute), Elution-1 (1:00-4:00 minutes), 
Elution-2 (4:00-5:00 minutes), Elution-3 (5:00-6:00 minutes), with most of the AChBP 
appearing in the second fraction. The second fraction was used for all the experiments, 
and other fractions were discarded. The process of medium adjustment, equilibration 
before and after purification, and protein purification takes 12-15 hours (for the AChBP 
and each mutant), depending on the volume of the culture medium. At this point, the 
purified protein (with imidazole) can be stored or used to verify presence of the protein 
by performing gel electrophoresis. Since His-Select columns enables purification of the 
AChBP in one-step from the AChBP/HEK-293 cells, the purified protein can also be 
directly transferred to sensor surfaces such as the scintillation proximity assay (SPA).
Eluted protein requires further purification, namely imidazole removal, to perform 
Lowry assay since imidazole interferes with protein quantification. Free imidazole was 
removed by passing the eluted protein (plus imidazole) through 10kD-MW Cutoff 
MicroSep centrifugal filters (Pall Life Science), and centrifuging at 7500 rpm for 40 
minutes. Three washes of 3-4 ml PBS/wash with centrifugation at 7500 rpm for 40 
minutes each were performed to remove excess imidazole. The protein was then 
removed from the filter by addition of 1-ml PBS.
2.5 Analysis of the AChBP
The His-Select purified and imidazole-free protein was analyzed by Lowry assay 
(Sigma), and polyacrylamide gel electrophoresis (PAGE) using standard methods 
(BioRad). Purification of the AChBP from the 0.4 mg/ml G418 cell line typically 
produced more than 1-mg of protein per liter of culture media as determined by Lowry 
assay. Therefore, this method produces sufficient protein for evaluation of the AChBP
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and the AChBP-derivatives using SPA, which was our standard method for evaluating 
the binding interactions.
The purity and the molecular weight of denatured and native AChBP and the 
AChBP-derivatives were characterized using PAGE under non-denaturing and 
denaturing conditions using standard methods. Precast 7.5%, to 12% tris-HCl gels 
(BioRad) were pre-run at 200V for 20-minutes before they were loaded with 4-^g of the 
protein samples and Kaleidoscope protein standard (BioRad) and ran for another 40-60 
minutes at 120V. Gels were stained with Coomassie Brilliant Blue at room temperature 
by shaking for 1-2 hours, followed by de-staining with dH2O for 30-minutes. The 
AChBP was identified as the 37kD band under denatured conditions, and as the 150kD 
under non-denaturing conditions. These results showed that the protein was expressed 
as a pentamer, as expected. The AChBP in samples was also visually estimated to be 
highly pure. No bands of similar molecular weight were observed in a control, un­
transfected HEK-293 culture media sample (Figure 3.4).
2.6 Storage of the AChBP
In order to facilitate storage and increase stability of the AChBP, we lyophilized 
the purified AChBP protein, and then reconstitute it. The eluted AChBP in PBS was 
aliquoted into 200-^1 portions and placed in 2-ml micro-centrifuge tubes. The tubes 
were spun, uncapped, under vacuum in a rotatory evaporator (Savant Instruments, DNA 
Speed Vac) at room temperature for 2.5-3 hours until dry. The samples were then 
refrigerated at 2-8 °C for up to 12-months. The dried samples were rehydrated and 
tested immediately after drying, as well as 6-months and 12-months after drying, using 
PAGE or SPA assays, and then compared to samples before drying. The results 
showed no differences in protein composition or binding characteristics (data presented 
in Chapter 3.5). The stability of the AChBP protein for long-term storage and the fact 
that it can be easily dried and reconstituted, and transported are added benefits that 
should facilitate the AChBP-related experiments.
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2.7 Pharmacological Characterization of the AChBP
To determine if the binding characteristics of the mutated proteins were intact, we 
utilized a Scinitillation Proximity Assay (SPA) using the serotonin antagonist [3H]- 
granisetron. SPA also utilizes PVT Copper His-tag SPA beads, where the copper on 
the beads bind to the 6X His tag engineered into the C-terminal of the AChBP (110). 
Scintillant is integrated into the bead matrix, thus the bead fluoresce only when a 
radioisotope is in close proximity to it, and molecules not in close proximity to the bead 
do not fluoresces and do not contribute to the signal (Figure 1.6). Since only bound 
molecules produce a signal, no filtration or other separation technique is necessary to 
distinguish bound from unbound ligand. This enables rapid analysis of binding data, as 
well as the use of low affinity ligands. In addition, SPA enables rapid evaluation of 
radioligand binding characteristics with minimal amounts of protein. We used this 
technique for pharmacological characterization of the AChBP, and as our standard 
method of evaluating the binding interactions for the AChBP and AChBP-derivatives.
SPA assays were performed in 200 ^l reaction vessels containing protein, 
radioligand, and SPA beads. For the AChBP binding assays, the protein concentration 
was held constant and the [3H]-granisetron was added in variable concentrations. The 
protein (the AChBP and AChBP-derivatives) was added to anti-His SPA beads 
(GE/Amersham Biosciences), at a concentration of 10 nM per well. The SPA beads 
were diluted with phosphate-buffered saline (PBS) and Bovine Serum Albumin (BSA, 
Sigma; 5 mg/ml) to a final concentration of 0.2 mg/ml per well before they were added 
to protein. BSA was added to decrease non-specific binding. The protein/bead mixture 
was incubated at ~21 ° C (room temperature) for a minimum of 1-hour. Then, six 
different concentrations of radioligand, [3H]-granisetron, increasing by approximately 
three-fold intervals from 0-to-300 nM (0, 3, 10, 30, 100, and 300 nM) were added to the 
protein/bead mixture. The mixtures in the reaction vessels were incubated at ~21 ° C 
(room temperature) on a shaker with low speed for a minimum of 2-hours before 
counting. Non-specific binding was determined in the presence of 1-M acetylcholine 
since it strongly binds to the AChBP, and subtracted from the total binding.
For competition assays, the [3H]-granisetron concentration was held constant 
and used as the radioligand in competitive binding, and the competing ligand was
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added in variable concentrations. The purpose of theses assays was to determine the 
affinity (Ki value) of compounds that were not available in radiolabeled form. Therefore, 
the Kd value of the [3H]-granisetron for the AChBP and AChBP-derivatives (using10nM 
of protein, 5 mg/ml BSA, 0.25 mg/ml SPA beads, and 6-different concentrations of [3H]- 
granisetron), were calculated using one-site binding model and GraphPad Prism 
software. This Kd value was used as [3H]-granisetron concentration in the assays. For 
competition assays, 8-12 concentrations of competing ligand, increasing by 
approximately three-fold intervals from 0-to-3000 ^M, were added to the protein/bead 
mixture. These assays were carried out using the same concentration of protein and 
reagents, and in the similar manner as the binding assays.
Radioactivity level was measured by counting the samples for a minimum of 4- 
hours using a 1450 Microbeta Plus liquid scintillation counter (Perkin-Elmer). Each 
count is taken over one minute per sample and then averaged. This is considered one 
round of counting, which is repeated every 15 minutes. Therefore, each sample well is 
counted many times (at every 15-minute interval) depending on the length of time a 
scintillation counter is running. The optimal output occurred 2-3 hours after the samples 
had been placed in the scintillation counter for counting. Longer time periods likely 
resulted in a settling of the SPA beads, producing uneven counting and higher 
background noise. Shorter periods produced highly unstable readings, likely due to pre­
equilibrium conditions. The results from 5-rounds of plate reading were averaged and 
used for analysis. Kd and Ki values were determined from this information using non­
linear fitting and GraphPad Prism software. The data reported in this Dissertation 
resulted from the average of at least four experiments.
2.8 Data Analysis for the AChBP
The equilibrium binding constant or dissociation constant (Kd) for the [3H]- 
granisetron radioligand was calculated directly from a plot of radioligand concentration 
versus fraction bound. Data was analyzed using GraphPad Prism software. The Kd 
value was calculated using the simple one-site binding model shown below:
Y = Bmax * X / Kd + X
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where X is the [3H]-granisetron radioligand concentration, Y is the amount of bound 
ligand in counts per minute (CPM), Kd is the binding affinity, and Bmax is the calculated 
maximal binding.
Competition assays determine the IC50 value (in nM or ^M), which represents the 
concentration of a ligand/drug that is required for 50% inhibition. The IC50 of cold (non­
radioactive) ligands for the inhibition of [3H]-granisetron was determined by using the 
sigmoidal dose-response equation below and GraphPad Prism software:
Y = Bmax / (1 + 10 ([log(IC50)-X] * n) ) 
where X is the logarithm of the concentration of cold ligand, Y is the response in count 
per minute (CPM), and n is the Hill-slope.
The Ki value shows the concentration of the drug that binds to half of available 
receptor binding sites. Ki was calculated using the Cheng-Prusoff equation:
Ki = IC50 / (1+L/Kd)
2.9 Mutation of the AChBP
The AChBP, custom synthesized by GeneArt Inc. (Germany), was mutated with 
single and double amino acid substitutions from equivalent positions in the 5- 
hydroxytryptamine type 3 receptor (5-HT3R) sequences. The goal was to construct a 
serotonin-binding protein by modification of the AChBP residues to recognize serotonin 
ligands, as well as synthesize and purify these mutated proteins in quantities usable for 
biosensor applications. The construction of a serotonin-binding protein would enable 
the development of a molecular biosensor for serotonin.
The AChBP amino acids for single-site and double-site mutations were 
determined as explained in Chapter 4. Oligos to mutate amino acids were designed 
using the DNA Strider program, quality checked with Basilisk (a Mac emulator), and 
ordered through The Midland Certified Reagent Co., Inc. Once oligos arrived, 
mutations were constructed utilizing the QuickChange II Site-Directed Mutagenesis kit 
(Stratagene’s), which is designed for rapid and efficient incorporation of insertions, 
deletions and substitutions into double-stranded DNA. We used the standard methods 
and protocol of the kit with the following modifications: 50 ng of AChBP DNA and a pair 
of designed oligos for a specific mutation were used for each Polymerace Chain
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Reaction (PCR). The PCR machine was programmed for 18 cycles of denaturation for 
1-minute at 95 °C, annealing for 1-minute at 60-65 °C (it was always 10 °C less than 
oligo’s temperature), and extension for 9-minutes at 68 °C. The PCR products in each 
test tube was treated with 1- ^l of DpnI restriction enzyme (20,000 units/ml), and 
incubated for 1-hour at 37 °C to digest methylated parental DNA.
XL-1 blue supercompetent E.Coli cells were transformed with 4- ^l of DpnI- 
treated DNA using standard protocol and reagents (Stratagene). DNA was purified 
using Mini-prep and Maxi-prep (Qiagen), and the presence of the insert was verified by 
restriction digest and agarose gel electrophoresis. The verified mutant DNA was sent to 
Sequetech for commercial sequencing (Sequetech Corp, Mountain View,
CA, http://datasytem. sequetech.com).
Once presence of the DNA substitution was verified by Sequetech, the mutated 
DNA was transfected into HEK-293 cells to develop stably transfected cell lines that 
secrete a mutated AChBP protein into the extracellular medium in a manner similar to 
that used to produce the wild-type AChBP and explained in Chapter 2.3. The mutant 
DNA was then purified, analyzed, stored, and pharmacologically characterized using 
SPA. It should be noted that the construction, development, amplification, expression 
and testing of each mutant receptor took approximately one year.
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Chapter 3: Expression and Validation of the AChBP 
as a Viable Biosensor Protein
3.1 Acetylcholine-binding Protein (AChBP)
Research into ligand-gated ion channel (LGIC) structure has been greatly 
facilitated by the discovery of the acetylcholine-binding protein (AChBP) in the great 
pond snail, Lymnaea Stagnalis (99). Two additional homologs of this protein have also 
been identified in the freshwater snail Bulinus truncates (98), and sea hare Aplysia 
californica (111). The AChBP protein in these molluscs is secreted by glia cells, and its 
role is postulated to involve regulation of synaptic function through binding and inhibition 
of acetylcholine (96,99). It is also hypothesized that the AChBP could help defend 
snails against nicotinic toxins, which are common in aquatic species, by binding to the 
toxins before they reach the receptors (96,99). Sequence alignment of the AChBP 
shows a high similarity to the extracellular, N-terminal ligand-binding domains of various 
cys-loop LGICs, and specifically the nicotinic acetylcholine (nACh) receptor 
(93,95,101,102,105), and sequence analysis suggests that this protein may have 
evolved as a result of a nACh receptor truncation in ancestral snails (96).
Structural data for the AChBP confirms much of what has been reported from 
previous studies on LGIC receptors. Like LGICs, this protein assembles in a 
pentameric form, and the binding site of the AChBP is composed of the same structural 
loops (or pockets) hypothesized for the LGIC family of receptors (99). Within these 
loops, amino acid side chains and the protein backbone make contacts with nicotine (or 
other orthosteric ligands) (95,99). The AChBP, like the nACh receptor, contains a 
crucial cys-cys loop that is involved in structuring the ligand-binding domain, as well as 
conserved residues at the ACh binding site (95,99,104). In addition, the AChBP binds 
to nACh receptor agonists and antagonists including Ach (112), nicotine (101), a- 
bungarotoxin (100), and epibatidine (111).
The AChBP has a high sequence homology (15-30%) with the amino terminal 
domain of LGIC receptors (20,99). The water-soluble nature of the AChBP and its 
similarity in structure to LGICs has enabled the determination of a high resolution crystal 
structure (2.7 A) of the AChBP (Figure 3.1), that has been used as a template for
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Figure 3.1: X-Ray S tructure o f A ce ty lcho line -b ind ing  Protein (AChBP) in Com plex w ith  N icotine 
and Carbam ycholine. From Lymnaea Stagnalis (Great Pond Snail), at 2.5 A resolution, from Protein 
Data Bank (PDB) file 1UV6.
homology modeling of N-terminal binding domains of cys-loop LGICs (93,95). Models 
of LGIC receptor binding sites have been developed based on the AChBP crystal 
structure to study and analyze receptor-ligand interactions. These models have been 
further refined using site-directed mutagenesis methods (97,107,113-115).
The similarity of the AChBP binding site to LGIC binding domains also raises the 
possibility that the AChBP could be used to mimic LGIC receptors, acting as a potential 
lead molecule for a family of biosensor proteins. In addition, since the AChBP is a 
soluble protein that is easily expressed and purified (112,113), it is an ideal biosensor 
molecule that can be easily attached to biosensor surfaces. It is also possible that the 
AChBP protein can be modified to detect different classes of ligands for different 
receptors (94).
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This chapter describes exploration and development of the AChBP protein as a 
sensor protein, as well as evaluation of its structure, functionality and stability.
3.2 Engineering of the AChBP
The AChBP was custom synthesized to specifications that facilitate the proposed 
engineering and biosensor applications of this project using commercial AChBP DNA 
from the great pond snail, Lymnaea stagnalis. In order to rapidly develop stable cell 
lines for protein production, the synthetic AChBP gene was inserted into the p3xFLAG- 
CMV-9 expression vector (Figure 3.2). The vector contains ampicillin resistant genes 
for selection in bacterial cell lines; neomycin resistant genes, which confer resistant to 
the antibiotic G418, for use in selecting transfected mammalian cell lines (HEK-293); 
and an MCS (multiple cloning site) on its C-terminal. In addition, some modifications to 
the AChBP sequence were made to provide for ease of purification and/or attachment 
to sensor surfaces, such as a C-terminal 6X His tag and an N-terminal FLAG tag.
The C-terminal 6X His tag allows the protein to bind to metals such as copper 
and nickel to facilitate rapid protein purification. This tag can also be used for protein 
immobilization on nickel containing surfaces such as the scintillation proximity assay 
(SPA) beads. The N-terminal FLAG tag was added to provide a secondary option for 
purification using an anti-FLAG antibody for protein detection and characterization, as 
well as its immobilization. The vector also contains a pre-protrypsin leader peptide 
preceding the FLAG tag to allow for secretion of the AChBP into the extracellular 
medium, and provide for ease of recovery of the protein. A similar N-terminal FLAG and 
C-terminal 6X His AChBP was previously expressed and used by Hansen et al. (116). 
Both tags were shown to be accessible and used for purification, and do not seem to 
interfere with normal binding (96). Thus, the FLAG and His tags do not appear to affect 
the AChBP/ligand binding. A comparison of sequence data between the AChBP DNA 
and the p3xFLAG-CMV-9 expression vector/AChBP indicated that the vector was 
created as indicated above (Figure 3.3).
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Figure 3.2: p3XFLAG-CMV-9 Expression Vector. The AChBP gene was inserted into this vector.
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A. The AChBP DNA Sequence:
sp|P58154|ACHP_LYMST Acetylcholine-binding protein
OS=Lymnaea stagnalis PE=1 SV=1 Source: http://www.uniprot.org/uniprot/P58154
MRRNIFCLAC LWIVQACLSL DRADILYNIR QTSRPDVIPT QRDRPVAVSV SLKFINILEV 
NEITNEVDVV FWQQTTWSDR TLAWNSSHSP DQVSVPISSL WVPDLAAYNA ISKPEVLTPQ 
LARVVSDGEV LYMPSIRQRF SCDVSGVDTE SGATCRIKIG SWTHHSREIS VDPTTENSDD 
SEYFSQYSRF EILDVTQKKN SVTYSCCPEA YEDVEVSLNF RKKGRSEIL
B. Coding Sequence Obtained from the p3XFLAG-CMV-9 / AChBP Expression Vector:
M DYKDHDGDYK DHDIDYKDDD DKRRNIFCLAC LWIVQACLSL DRADILYNIR QTSRPDVIPT 
QRDRPVAVSV SLKFINILEV NEITNEVDVV FWQQTTWSDR TLAWNSSHSP DQVSVPISSL 
WVPDLAAYNA ISKPEVLTPQ LARVVSDGEV LYMPSIRQRF SCDVSGVDTE SGATCRIKIG 
SWTHHSREIS VDPTTENSDD SEYFSQYSRF EILDVTQKKN SVTYSCCPEA YEDVEVSLNF 
RKKGRSEIL HHHHHH
Figure 3.3: DNA Sequence. (A) is the published DNA sequence data for the AChBP, which is also 
shown in bold in (B). (B) is the coding region of the p3XFLAG-CMV-9/AChBP expression vector. 
Comparison of A-and-B shows the two sequences are 100% identical. The protein produced by the 
expression vector is a fusion protein with A-terminal His. This protein was verified by DNA sequencing.
3.3 Production and Purification of the AChBP
The AChBP was expressed and purified using methods outlined in Chapter 2 
(Materials and Methods). Briefly, the AChBP/ p3xFLAG-CMV-9 vector was transformed 
into XL-1 blue supercompetent E.Coli cells using standard protocol and reagents 
(Stratagene). DNA was purified using mini-prep and maxi-prep (Qiagen), and the 
presence of AChBP DNA insert was verified by restriction digest and agarose gel 
electrophoresis. The DNA was sequenced by commercial sequencing (Sequetech 
Corp, Mountain View, CA, http://datasytem. sequetech.com).
The verified AChBP/p3xFLAG-CMV-9 DNA was transfected into HEK-293 cells 
using the SuperFect reagent kit and protocol (Qiagen). A stable cell line expressing the 
His-tagged AChBP in HEK-293 cells was developed which actively secreted the AChBP 
into the medium. Culture medium containing the AChBP protein was purified using 
Nickel-EDTA His-Select Columns (Sigma). This step was followed by imidazole 
removal via passing the protein through 10kD-MW Cutoff MicroSep centrifugal filters 
(Pall Life Science), centrifuging at 7500 rpm for 40 minutes, three washes of 3-4 ml 
PBS/wash with centrifugation at 7500 rpm for 40 minutes each, and final elution of the 
protein from the filter by addition of 1-ml of PBS.
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Purified protein was analyzed by Lowry assay and polyacrylamide gel 
electrophoresis using precast tris-HCl polyacrylamide gels. Gel electrophoresis was 
performed under denaturing and non-denaturing conditions (Figure 3.4). The AChBP 
protein was identified as the 37kD single band under denatured conditions which is 
expected for the monomeric protein, and about 150kD under non-denatured conditions. 
Since the non-denatured protein was approximately 5X the size of the denatured 
protein, it was concluded that the AChBP protein was expressed as a pentamer. No 
bands of similar molecular weight were observed in the control, untransfected HEK-293 
media sample. Above information are consistent with literature values for the AChBP 
and indicate the secreted protein assembles correctly with a pentameric structure.
3.4 Yield Increase of the AChBP
As noted in Chapter 2, the purification columns were purchased from Sigma 
Corporation, and the standard protocol was used in initial experiments; however, the 
protein yield was low (285 ^g/L of media) and insufficient. The original protocol for 
extract preparation calls for: a) addition of salts at the concentrations of 50mM sodium 
phosphate (monobasic, Na2HPO4),0.3M sodium chloride (NaCl), and 10mM imidazole;
b) adjustment of pH to 7.5 using 1M sodium hydroxide (NaOH), and; c) filtration through 
0.4-^m cellulose acetate filters. Addition of imidazole to the media served to decrease 
non-specific protein binding to the affinity column, resulting in a higher yield and highly 
pure final product; and NaCl was used to increase the ionic strength of the solution.
After many experiments over an extended period of time, we modified the extract 
preparation protocol which resulted in a 5-fold increase in the protein yield (1,398 ^g/L 
of media). Collected medium was treated and prepared as follows before it was 
introduced to the purification columns: a) addition of salts at the concentrations of 50mM 
sodium phosphate (monobasic, Na2HPO4),0.3M sodium chloride (NaCl), and 10mM 
imidazole; b) adjustment of pH to 8.0 using 1M sodium hydroxide (NaOH), and; c) 
filtration through 0.2-^m cellulose acetate filters. A higher pH helped with the complete 
elution of the salts, resulting in a higher protein yield; and a filter with smaller pores 
produced a cleaner extract to be run on the columns. These modifications resulted in
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Figure 3.4: Polyacrylamide Gel Electrophoresis of the AChBP. Purity and assembly of the AChBP 
was determined using native and denaturing PAGE. The right hand gel shows the results of PAGE (non­
denaturing conditions) and the left hand gel shows the result of separation under denaturing conditions 
(SDS PAGE). Gels were stained with coomassie blue stain (BioRad). The protein sample lane is indicated 
by S and the BioRad Kaleidoscope standard is indicated by Std. Under non-denaturing conditions, a 
distinct band is shown to migrate similar to the 150kD standard. Under denaturing conditions, the 
dominant band shifts to slightly less than 37 kD. The molecular wt of the native protein of about 150kD is 
consistent with the predicted molecular wt of the pentameric AChBP. The 37 kD single band in the 
denaturing gel is as expected for the monomeric protein. In the non-denatured protein, a smaller band is 
evident at around 37kD as well suggesting some unassembled monomers are present.
production of more than 1-mg of pure protein for every liter of culture media as 
determined by Lowry assay.
3.5 Storage of the AChBP
For a protein to be considered a biosensor, it must meet a number of criteria 
including the ability to produce it in sufficient quantity, ease of transportation, stability 
and sensitivity to different ligands. As described above, the AChBP can be produced 
and purified easily in sufficient quantities. Larger quantities are likely achievable using 
non-mammalian expression systems such as insect cells; however, the quantities
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described here are sufficient for immobilization of the protein on bead or chip-based 
systems and so, no further enhancement was developed in this project.
Our initial data from binding assays performed over a period of time, using the 
same fresh AChBP were not consistent (data not shown). Hansen et al. (97) reported 
pentamer-dimerization of stored AChBP which might explain our declining results over 
an extended timeframe. We observed that imidazole appeared to improve the stability 
of the AChBP when stored at 2-8 °C. As described above, imidazole is removed before 
the Lowry assay since it interferes with the assay. However, imidazole removal is not 
necessary for binding assays using the SPA biosensor since SPA is both an affinity 
purification step and an analysis platform. The AChBP stability in imidazole is most 
likely due to stabilization of the single pentamer structure and prevention of pentamer- 
dimerization (or clumping of proteins). Imidazole may bind to the orthosteric binding 
site, and is thus likely removed during the wash step after immobilization of the protein 
on the bead or chip surface. Previous data from our laboratory showed that presence of 
imidazole did not interfere with protein binding or influence binding data when used in 
the SPA system (113).
In order to increase the AChBP stability and facilitate its storage, a member of 
our laboratory attempted to dry the purified AChBP, and reconstitute it with distilled 
H2O. It was shown that the AChBP was resistant to denaturation, could be easily dried 
and reconstituted, and its stability was greatly increased in dried samples (113).
3.6 Biosensor Platform for the AChBP
The soluble nature of the AChBP protein, its relative ease of production and 
purification, as well as stability in storage and transportation makes it an ideal potential 
biosensor protein. However, to be considered as an effective biosensor molecule, the 
potential protein must also function correctly and provide reasonable signal when 
attached to biosensor surfaces and exposed to ligands. To determine the binding 
characteristics of the AChBP protein, we utilized the scintillation proximity assay (SPA) 
as the biosensor surface and our standard method of evaluating binding interactions of 
the AChBP with different ligands.
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The SPA is a bead-based assay which utilizes SPA beads coated with a 
Scintillant (82,117). The protein of interest is bound to the bead surface using antibody 
binding or copper chelation. The protein and bead mixture is then exposed and 
incubated with a radioligand. After an appropriate incubation time, the 
protein/bead/radioligand complex is placed in a scintillation counter to determine the 
amount of ligand bound in close proximity to the bead surface (Figure 1.6).
The SPA assay is conducted similar to the conventional radioligand binding 
assays, but it represents a technological advance over the conventional assays as it 
does not require filtration of the protein prior to counting. In traditional ligand-receptor 
binding, the filtration step is designed to separate bound and unbound ligands prior to 
scintillation counting; however, the scintillant incorporated into the SPA beads only 
responds when the radioligand is bound in close proximity to the bead. Thus, a signal is 
only seen when radioligand is bound, and no separation step is required. This permits a 
high throughput binding study to be performed.
The SPA technique enables rapid evaluation of radioligand binding 
characteristics with minimal amounts of protein. Since SPA does not have a filtration 
step, this assay can be used with lower affinity ligands as there is no danger of washing 
away a low affinity ligand during washing of the filters. In addition, lack of filtration step 
makes it easier to automate the SPA technique and develop high throughput assays. 
Taken together, it seems the SPA assay is well suited to a soluble protein like the 
AChBP or engineered AChBP derivatives. To utilize the SPA assay for the project 
described here, we modified the standard SPA protocol to be able to test the 
functionality of the AChBP. These modifications are discussed below, and all the 
assays reported in this section were run a minimum of four times.
3.6.1 The SPA Bead Concentration
The SPA assay protocol is described in Chapter 2. Briefly, the SPA assays were 
performed in 200 ql reaction vessels containing protein, radioligand, and the SPA 
beads. For the AChBP binding assays, the protein concentration was held constant and 
the [3H]-granisetron was added in variable concentrations. The protein (AChBP and 
AChBP-derivatives) was added to anti-His SPA beads (GE/Amersham Biosciences).
39
The SPA beads were diluted with phosphate-buffered saline (PBS) and Bovine Serum 
Albumin (BSA, Sigma) before they were added to protein. BSA was added to decrease 
non-specific binding. The protein/bead mixture was incubated at ~21 ° C (room 
temperature) for a minimum of 1-hour. Then, six different concentrations of radioligand, 
[3H]-granisetron, increasing by approximately three-fold intervals were added to the 
protein/bead mixture. The mixtures in the reaction vessels were incubated at ~21 ° C 
(room temperature) on a shaker with low speed for a minimum of 2-hours before 
counting. Non-specific binding was determined in the presence of 1-M acetylcholine 
since it strongly binds to the AChBP, and subtracted from the total binding.
In the SPA assay, the AChBP protein is immobilized by binding it to the beads 
using the incorporated 6X His tag on the C-terminal. Since scintillant is integrated into 
the bead matrix, no filtration is necessary for separation of bound and unbound ligand 
while using this system as only radioligand bound at close proximity to the bead excites 
the scintillant and produces a signal. This enables analysis of binding data as well as 
use of low affinity ligands. Thus, preparation of the beads is an essential step in the 
SPA assay.
Initial SPA data, using 0.5 mg/ml of beads, showed high background binding 
which could be attributed to a) high concentration [3H]-granisetron, and thus non­
specific binding of the radioligand to the beads or binding of radioligand at a secondary, 
low affinity sites on the AChBP protein itself; b) high concentration of the beads which 
can lead to non-proximity effect, (where the bead would be activated when in close 
proximity of a radioligand, irrespective of whether the radioligand is bound to the bead);
c) low concentration BSA resulting in non-specific binding; or d) low concentration of the 
protein. To address non-specific binding of [3H]-granisetron to the beads, the protein 
was pre-incubated with beads before addition of [3H]-granisetron; however, this 
modification did not decrease the high background signal. To address the possibility of 
high concentration of beads, a bead-titration test (0.1-to-0.5 mg/ml of beads) was 
carried out to find the optimal concentration of beads. The SPA data showed there 
were more than enough beads at 0.3 mg/ml concentration (data not included). Further
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Figure 3.5: The SPA Bead Concentration. Top graph shows count per minute (CPM) vs concentration 
of radioligand granisetron for both 0.15-and-0.2 mg/ml of beads (continued on the next page).
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Figure 3.5 (continued): Middle graph shows the same data in Log format. Bottom graph is B/Bmax vs 
radioligand granisetron concentration for both 0.15-and-0.2 mg/ml of beads. CPM vs radioligand 
concentration placed the optimal bead concentration at 0.2 mg/ml. The bottom graph shows lower Kd 
(dissociation constant) for 0.2 mg/ml of beads, thus validating the result of other figures.
tests were carried out, and the results placed the optimized amount of SPA beads at 0.2 
mg of beads per ml (Figure 3.5).
3.6.2 Counting by the Scintillation Counter
In the SPA assay, the protein/bead/radioligand complex is incubated at ~21 ° C 
(room temperature) on a shaker with low speed for a minimum of 2-hours before the 
radioactivity level is measured using a scintillation counter. Each count is taken over 
one minute per sample and then averaged. This is considered one round of counting, 
which is repeated every 15 minutes. Therefore, each sample well is counted many 
times (at every 15 minutes interval) depending on the length of time a scintillation 
counter is running. To find the most stable results, we ran the scintillation counter for 4 
hours, using the AChBP protein/SPA beads/[3H]-granisetron, and evaluated the results 
at every one hour interval. The optimal output occurred 2-3 hours after the samples had 
been placed in the scintillation counter for counting. Longer time periods likely result in 
a settling of the SPA beads, producing uneven counting and higher background noise. 
Shorter periods produced highly unstable readings, likely due to pre-equilibrium 
conditions. Based on these data, we chose the 2-3 hour incubation period as the 
optimal incubation time that produced reliable, stable and reproducible results (Figure 
3.6).
3.6.3 The SPA Bovine Serum Albumin (BSA) Concentration
BSA was present in all the solutions used in an SPA assay, including the bead 
solution and protein solution. The primary purpose of adding BSA was to decrease 
non-specific binding. The standard protocol for the SPA-beads called for 0.05 mg/ml of 
BSA. However, this concentration of BSA resulted in a very high background binding
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Figure 3.6: Measurement of Radioactivity Level Using the Scintillation Counter. The graph 
illustrates measurement of radioactivity level for 4-hours at 1-hour interval (corresponding to plate 
readings #4, 8, 12, and 16 respectively), using the data from samples read and counted by the 
Scintillation Counter. The data shows best radioactivity reading time is about 2-3 hours (plate readings 
#8-12) after the samples have been placed in the scintillation counter for counting.
* AChBP (#4)
* AChBP (#8)
'  AChBP (#12)
* AChBP (#16)
(approximately 50% of total reading). To address high non-specific binding, a BSA- 
titration test (0.5-to-4.0 mg/ml) using 0.2 mg/ml of beads was performed. The results 
showed a 37-39% decrease in non-specific binding as the BSA concentration 
increased. Based on these data, it was determined that 5 mg/ml of BSA was optimal for 
use in these SPA assays (Figure 3.7).
3.6.4 The SPA Protein Concentration
In order to increase specific binding, the non-specific binding had to be reduced, 
typically through adjustment of the BSA concentration. However, at the same time, 
specific binding needs to be increased by optimizing the concentration of the receptor 
protein. The concentration of the AChBP protein used in experiments, based on 
previous studies and data from our lab, was 5.8 nM. A protein-titration test (1.25-to-20 
nM) using 0.2 mg/ml of beads and 5 mg/ml of BSA was carried out to find the most 
advantageous concentration of the AChBP protein for the SPA assay in this project.
The results showed an increase in specific binding as the protein concentration 
increased. The specific binding was most stable with a protein concentration of 10nM
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Figure 3.7: Bovine Serum Albumin (BSA) Titration Test. Different concentrations of BSA, SPA beads 
and radioligand granisetron were used to address high non-specific binding in SPA assay. Top graph 
shows an increase in specific binding, and bottom graph shows a decrease in non-specific binding as the 
BSA concentration increased.
AChBP protein (Figure 3.8).
3.7 Functionality of the AChBP
Once conditions for the SPA assay were optimized for binding of [3H]- 
granisetron, additional binding characteristics of the AChBP protein were explored. For
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Figure 3.8: The SPA Protein Titration Test. SPA beads, radioligand granisetron, and different 
concentrations of protein were used for this experiment. Count per minute (CPM) versus protein 
concentration showed an increase in specific binding as well as a decrease in non-specific binding as the 
protein concentration increased. The specific binding leveled off at 10nM protein concentration, when all 
the available beads were utilized.
these assays, the AChBP was immobilized on the SPA beads under optimized 
conditions as described above (0.2 mg/ml beads, 5 mg/ml BSA and 10 nM AChBP). 
The 6X His tag on the C-terminal of the AChBP binds to copper on the SPA beads 
resulting in immobilization of the protein on the bead surface. Different concentrations 
of radioligand, [3H]-granisetron, were incubated with the protein/bead complex, and the
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fraction of bound radioligand was determined by a scintillation counter after a 2 hour 
incubation period. Nonspecific binding was determined in the presence of 1.0 M 
acetylcholine, and was subtracted from total binding to give the specific binding of [3H]- 
granisetron to the AChBP.
To further evaluate the AChBP functionality as a potential biosensor molecule, 
we explored its ability to interact with other nicotinic ligands in competition with [3H]- 
granisetron. Since the AChBP is known to bind ligands which also bind to nicotinic 
acetylcholine (nACh) receptor (100,101,111,112), we tested the nicotinic receptor 
agonist acetylcholine, as well as the nicotinic receptor antagonist d-tubocurarine (dTC).
The nACh receptor is a cation-selective member of the pentameric ligand-gated 
ion channel (LGIC) family also commonly referred to as the "Cys-loop” family (4,5). 
Other members of this family include serotonin type 3 receptors (5-HT3), glycine and 
GABA receptors (4). Since the primary goal of this Dissertation is to evaluate the 
AChBP as a potential lead molecule in the development of a soluble biosensor protein 
that mimics the 5 -HT3 receptor, we also evaluated the binding of serotonergic ligands to 
the AChBP using the SPA assay. Previous data from our laboratory showed that the 
AChBP protein binds tightly to serotonin antagonists granisetron and dTC, but it binds 
weakly to serotonin receptor agonists such as serotonin (113). In these experiments, 
we assayed the following ligands: serotonin (a serotonin receptor agonist); 5-HT3 
receptor partial agonists m-chlorophenylbiguanide (mCPBG) and 2-Methyl-serotonin (2- 
Me-5HT); and the 5-HT3 receptor antagonist granisetron (9,19).
The data in this section is divided into: a) direct binding of the AChBP with [3H]- 
granisetron, and b) competition binding assays using the nicotinic and serotonergic 
ligands described above. Both types of binding assays utilized the SPA as the 
biosensor platform.
3.7.1 The AChBP Binding Assay
For evaluation of [3H]-granisetron binding, 10 nM of the AChBP protein, 5mg/ml 
of BSA, and 0.2 mg/ml of the SPA beads per sample well were used. [3H]-granisetron 
concentrations were varied between 0.00-and-100 nM. Similar to conventional binding 
assays, the equilibrium binding constant or dissociation constant (Kd) for the radioligand
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[3H]-granisetron was determined from a plot of radioligand concentration vs. fraction 
bound. Data was analyzed using GraphPad Prism software. The Kd value was 
calculated using the simple one-site binding model shown below:
Y = Bmax * X / Kd + X 
where X is the radioligand [3H]-granisetron concentration, Y is the amount bound in 
counts per minute (CPM), Kd is the binding affinity, and Bmax is the calculated maximal 
binding. The Kd value for the [3H]-granisetron was determined to be 19.4 nM with the 
standard error of 4.5 (19.4 ± 4.5 nM) (Figure 3.9).
3.7.2 The AChBP Competition Assays
[3H]-granisetron was utilized as the radioligand in competitive binding assays. 
Competition experiments used the Kd value of the AChBP for [3H]-granisetron 
concentration in nM; therefore, the concentration of [3H]-granisetron was fixed at 20 nM. 
In addition, 10 nM of the AChBP protein, 5mg/ml of BSA, and 0.2 mg/ml of the SPA 
beads were added to each sample well. At least 8 concentrations of competitor ligand 
in 3-fold increasing concentrations were used to acquire the final data. Competing 
ligand was added prior to addition of the radioligand, and was incubated with the 
AChBP protein and the SPA beads for 1-hour at ~21 ° C (room temperature). Once 
radioligand was added, the combined mixture was incubated at room temperature on a 
shaker (with low speed) for a minimum of 2 hours before the radioactivity level was 
measured and counted by the scintillation counter.
Competition assays determine the IC50 value (in nM or ^M), which represents the 
concentration of a ligand/drug that is required for 50% inhibition. The IC50 of cold (non­
radioactive) ligands for the inhibition of [3H]-granisetron was determined by using the 
sigmoidal dose-response equation below and GraphPad Prism software:
Y = Bmax / (1 + 10 ([log(IC50)-X] * n) ) 
where X is the logarithm of the concentration of cold ligand, Y is the response in count 
per minute (CPM), and n is the Hill-slope.
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Figure 3.9: Kd for the AChBP. The dissociation constant (Kd) of the AChBP for the radioligand [3H]- 
granisetron was determined from a plot of radioligand concentration vs. fraction bound. The Kd value was 
calculated using the simple one-site binding model and GraphPad Prism software, and was determined to 
be 19.4 ± 4.5 nM.
d-tubocurarine Assay
d-tubocurarine (dTC) is an antagonist for nicotinic ACh, 5-HT3 receptor, and the 
AChBP (19,21). Nine concentrations of dTC were used to carry out this assay (Figure 
3.10A). The IC50 of dTC for the inhibition of granisetron was determined to be 14.4 nM. 
The result is consistent with the previous data from our laboratory indicating that the 
AChBP binds tightly to serotonin antagonists (113).
Acetylcholine Assay
Acetylcholine (ACh) is an agonist for both nicotinic ACh and the AChBP (19,21). 
Twelve concentrations of acetylcholine were used for this competition assay (Figure 
3.10B). The IC50 of acetylcholine for the inhibition of granisetron was 3.16 ^M which 
shows strong interaction and binding between the AChBP and ACh.
Serotonin Assay
Serotonin (5HT) is a serotonin receptor agonist (19,21). Eight concentrations of 
5HT were used to carry out this assay (Figure 3.10C). The IC50 of 5HT for the inhibition
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Figure 3.10A: dTC Inhibition Assay. The IC50 of dTC, an antagonist for nicotinic ACh, 5-HT3 receptor, 
and the AChBP, for the inhibition of granisetron was 14.4 nM.
Figure 3.10B: ACh Inhibition Assay. The IC50 of ACh, an agonist for both nicotinic ACh and the 
AChBP, for the inhibition of granisetron was 3.16 pM.
of granisetron was determined to be 640 pM, which is consistent with previous data 
from our laboratory regarding weak binding of the AChBP to serotonin agonists (113).
m-chlorophenylbiguanide Assay
m-chlorophenylbiguanide (mCPBG) is a partial agonist for serotonin receptor 
(19,21). Eight concentrations of mCPBG were used for this competition assay (Figure 
3.10D). The IC50 of mCPBG for the inhibition of granisetron was 344 pM. This data
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Figure 3.10C: 5HT Inhibition Assay. The IC50 of 5HT, a serotonin agonist, for the inhibition of 
granisetron was 640 gM.
shows a stronger interaction between mCPBG and the AChBP when compare to the 
data from serotonin competition assay. The result is likely due to structural differences 
in the binding site which has made mCPBG a partial-agonist for serotonin.
2-Methyl-serotonin Assay
2-Methyl-serotonin (2-Me-5HT) is a serotonin receptor partial agonist (19,21). 
Eight concentrations of 2-Me-5HT were used to carry out this assay (Figure 3.10E).
The IC50 of 2-Me-5HT for the inhibition of granisetron was 41 gM. This data shows a 
very strong interaction between 2-Me-5HT and the AChBP when compared to data from 
serotonin and mCPBG competition assays. The result is likely due to structural 
differences in the binding site which has made 2-Me-5HT to behave more like a 
serotonin antagonist (instead of partial-agonist) when interacting with the AChBP.
While the AChBP is not a ligand-gated ion channel, it has been shown that 
conformational changes occur upon binding of agonists, and that most likely, the 
AChBP protein shifts from a low affinity to a high affinity agonist binding conformation.
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Figure 3.10D: mCPBG Inhibition Assay. The IC50 of mCPBG, a partial agonist for serotonin, for the 
inhibition of granisetron was 344 pM.
Figure 3.10E: 2-Me-5HT Inhibition Assay. The IC50 of 2-Me-5HT, a partial agonist for serotonin, for the 
inhibition of granisetron was 41 pM.
3.8 Evaluation of the AChBP as a Sensor Protein using a Microcantilever 
Biosensor Platform
Based on our experience and success with the production and lyophilization of 
the AChBP protein, a large quantity of dried AChBP was sent to the laboratory of our 
collaborator, Dr. Hai-Feng Ji, to be tested using the microcantilever biosensor. In that 
work, microcantilever bending was used for an AChBP-analyte binding study, which has 
applications in drug screening and drug development. Binding of the AChBP to small
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molecules such as acetylcholine (AChBP full agonist), nicotine (AChBP partial agonist), 
and d-tubocurarine (AChBP antagonist) were studied to verify the specificity of 
microcantilever bending, resulting from binding of ligands to the AChBP receptor, and to 
identify any variation in binding kinetics for agonists versus antagonists. The data 
demonstrated that all the ligands produced a deflection of the microcantilever coated 
with the AChBP, which is the result of binding of ligands with the AChBP. The 
mechanism responsible for producing deflections of the AChBP-modified 
microcantilever in response to ligand binding may be due to a slight conformational 
change of the AChBP on the microcantilever derived from the binding of the ligands to 
the AChBP. The data showed that the Bmax for nicotine and d-tubocurarine were much 
less than that for acetylcholine, which reflects a difference in conformational change of 
the AChBP on the surface. Partial agonists and antagonist, such as nicotine and d- 
tubocurarine, would likely produce smaller conformational changes compare to a full 
agonist like acetylcholine. Taken together, the results demonstrated that the AChBP 
binds to different agonists and antagonists, and that the AChBP-modified 
microcantilever can be used to study the interactions of small molecules with the 
AChBP. These results were published in a paper entitled “Micromechanical 
measurement of the AChBP binding for label-free drug discovery”(118). The similarity 
of data from both the microcantilever and SPA assays validates the use of our synthetic 
AChBP as a viable sensor molecule.
3.9 Conclusion
The data presented in this chapter demonstrated the successful production of the 
AChBP protein using HEK-293 cells, as well as the AChBP synthesis, storage, 
attachment and utilization as a biosensor molecule. The data also validated the 
scintillation proximity assay (SPA) and the microcantilever assay as fast and effective 
biosensor platforms for determining the binding properties of different ligands to the 
AChBP protein. In particular, the ease of use and availability of the SPA platform 
proved to be very useful for developing a high-throughput analysis of receptor-drug 
interactions. The limitation of the AChBP is that it has a broader selectivity than the 
LGIC receptors; hence, modifications will be required to enable its use in drug
52
development. The goal of developing a soluble biosensor molecule with 5-HT3 
receptor-like selectivity is a primary goal of this thesis. The next chapter explores 
approaches to modification of the AChBP to mimic the 5-HT3 receptor.
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Chapter 4: Mutations of the AChBP
4.1 Introduction
As described in Chapter 3, the soluble nature of the acetylcholine-binding protein 
(AChBP), the effective production of the AChBP protein using HEK-293 cells, and its 
successful purification and subsequent utilization as a biosensor protein makes the 
AChBP an ideal lead molecule for developing a family of biosensor proteins. In 
addition, the scintillation proximity assay (SPA) experiments in Chapter 4 demonstrated 
the potential of SPA for high-throughput screening application, as well as the AChBP as 
an ideal biosensor molecule for attachment to biosensor surfaces; both of which would 
be useful tools for drug screening and drug development.
The high sequence homology of the AChBP (15-30%) with the amino terminal 
domain of ligand-gated ion channel (LGIC) receptors (20,99), and the apparent 
structural similarity of the AChBP and LGIC binding sites (102,103) raises the possibility 
that the AChBP could be engineered for use as a biological sensor to mimic LGIC 
receptors (e.g. Glycine, GABA, Serotonin type 3), and detect LGIC ligands. In order to 
engineer an AChBP that selectively recognizes different classes of LGIC, the key amino 
acids in the binding site of the AChBP would need to be mutated to the homologous 
amino acids of the target LGIC receptor. This is the first step in developing a soluble 
homolog of a LGIC receptor. Prior to this study, no experiment of this type had been 
carried out despite the fact that the AChBP has been extensively used as a template to 
generate ligand-docked computer models of LGIC receptor to study and analyze 
receptor-ligand interactions (107,119).
Among members of the LGIC family of receptors, the AChBP appears to be most 
similar to the a7-nACh and serotonin type 3 (5-HT3) receptors (107,120), and is 
considered a naturally occurring, soluble homolog of the amino terminal region of these 
receptors (93,95,101,105). Both the a7-nACh and 5-HT3 receptors are monomeric 
pentameric receptors. Domains of these receptors have been shown to be so 
compatible that the amino terminal of an a7 receptor can be substituted in a 5-HT3 
receptor and produce a functional pentamer (121). This chimeric receptor responds to 
serotonin but has channel characteristics of the a7 receptor.
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Serotonin type 3 receptors are located in both the central and peripheral nervous 
systems (8,10). The ion channel of this receptor, like the nACh receptor, is cation- 
selective, and mediates neuronal depolarization and excitation within the nervous 
systems. The natural ligand of 5-HT3 receptor is serotonin, which modulates the 
release of multiple neurotransmitters such as dopamine, glutamate, epinephrine, and 
GABA (10). 5-HT3 receptors are involved in multiple nervous system disorders 
including alcohol and drug dependence, anxiety, depression, schizophrenia, sleep, 
cognition, memory, and chemotherapy-induced and post-operative nausea and vomiting 
(13,15,122). Thus, there are multiple drugs to target these disorders including 
antidepressants, anxiolytics, antiemetics, antipsychotics, and antimigraine, and the 
ligands that target the 5-HT3 receptors are considered powerful therapeutic agents (13). 
As a result, 5-HT3 receptors have been targets of drug discovery efforts (15,123). The 
number of available ligands for the 5-HT3 receptors and the extensive structure-activity 
relationship (SAR) available for this receptor makes it an excellent model system for the 
AChBP engineering studies described in this thesis.
Alignment of the AChBP binding domain sequence with the equivalent amino 
terminal sequence of 5-HT3 serotonin receptor (Figure 4.1) reveals a significant 
structural similarity (99,115). While the AChBP has only a 20% sequence homology 
with the extracellular ligand-binding domain of 5-HT3 serotonin receptors (20), models 
of 5-HT3 receptors have been developed based on the AChBP crystal structure that 
accurately predict interaction of ligands with the receptor (18,115,124,125). From 
earlier studies on the nACh receptor, it was hypothesized that 5-HT3 receptor binding 
site was composed of six binding loops present in other LGIC receptors; and currently, 
most of the amino acids comprising the A-F binding loops have been identified (16,93). 
As a result, it has been noted that with the exception of GABA receptor, all LGIC 
receptors and the AChBP have a Tryptophan (W) in their aromatic box in the B-loop 
which is implicated in ligand binding (20,126).
In addition to structural similarity between the AChBP and 5-HT3 receptor, and 
the extensive SAR studies of the receptors, a large number of studies have been 
conducted to understand the binding interactions of 5-HT3 receptors and ligands
(17,120,124,127). Using ligand-docked models, both antagonist and agonist binding
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Figure 4.1: Sequence Alignment of Binding Loops in the AChBP and 5-HT3 Receptors. Aligned 
sequences: Lymnaea stagnalis AChBP (AChBP), murine 5-HT3 receptor (m5-HT3A R) (115), and human 
5-HT3 receptor (h5-HT3A R) (99). The underlined amino acid residues indicate their significance (mutations 
to alanine have a ten-fold or more effect on binding) for binding to 5-HT3 receptor agonist serotonin 
(blue); 5-HT3 receptor antagonist granisetron (red); 5-HT3 receptor antagonist lerisetron + agonist 
serotonin (purple); agonist serotonin + antagonist granisetron (green) (113).
models have been proposed for 5-HT3 receptor (16,20,120,125). Extensive site- 
directed mutagenesis has been used to identify structural and functional features of this 
receptor. Our laboratory has been particularly active in working with 5-HT3 receptors, 
and has conducted site-directed mutagenesis on loops A-D of the binding domain
(18,20,21,124). Molecular models based on these studies have been developed by 
previous graduate students to describe the binding of granisetron to the 5-HT3 receptor 
including all key residues thought to interact with granisetron (20,124). These models 
lead to the hypothesis that binding of granisetron to the AChBP would be similar to the 
5-HT3 receptor, and that the affinity of granisetron for both receptors would be similar 
based on the conservation of residues that are important for granisetron binding.
A comparison of mutagenesis data from the 5-HT3 serotonin receptor and 
structural data from the AChBP, as well as the deduced structural similarities between 
the two, suggests that similarly placed residues perform parallel functions in both the 
AChBP and 5-HT3 receptor (16,113,124). Taken together, it would seem that 
construction of a soluble serotonin-binding protein with specificity and sensitivity similar
57
to the human 5-HT3 receptors, which in turn could result in development of a molecular 
biosensor for serotonin, should be possible and would produce a valuable tool to use in 
drug development. In addition, this method can serve as a template for conducting 
similar studies on other LGIC receptors.
4.2 Experimental Approach
The structural similarity of the AChBP to other LIGC receptors suggests that the 
AChBP can be modified and engineered to mimic the selectivity of other receptors. The 
primary aim of this project is to engineer the AChBP to produce a water-soluble 
serotonin-binding protein (or biosensor) that precisely mimics the specificity of native 5- 
HT3 receptors.
To accomplish this aim, two approaches could be utilized to alter the specificity of 
the AChBP, namely, a) site-directed mutagenesis of the AChBP binding site, or b) 
construction of chimeric receptors incorporating regions of the 5-HT3 receptor into the 
AChBP. The two approaches are intended to provide two alternative paths to the same 
goal; however, they require different timeframes and provide distinct types of 
information. For example, site-directed mutagenesis experiments would take a long 
time to develop and carry out, but the end results provide valuable information regarding 
binding sites in both the AChBP and serotonin; whereas chimera experiments do not 
take as long as mutagenesis, but little data about binding sites would be gained since, if 
they are non-functional, it is difficult to determine the reason. Non-functional receptors 
could be the result of poor folding, transport or any number of other issues. We 
attempted an a7/AChBP chimera to determine if an a7-Binding Protein (a7-BP) could be 
quickly generated, but as described below, the complex did not appear to assemble 
correctly and completely. As understanding this lack of assembly clearly would require 
substantial additional study including site-directed mutagenesis, the studies described in 
this chapter are primarily focused on more methodical, site-directed mutagenesis.
4.2.1 Chimeric Approach: a7-Binding Protein Studies
Initial attempts to create a modified AChBP were based on the a7 receptor and 
the premise that the receptor could possibly be truncated prior to the M1
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transmembrane (TM1) region, if appropriate changes were made to eliminate 
hydrophobic pockets on the a7 protein that would be exposed when the receptor was 
removed from the cell membrane. A chimeric receptor was constructed using the amino 
terminal region of the a7 receptor combined with regions of the AChBP that are thought 
to contribute to its ability to express independent of a transmembrane domain. 
Specifically, the cys-loop region of the N-terminal domain of a7 receptor was replaced 
by the identical region of the AChBP; and a second substitution replaced the C-terminal 
end of the a7 receptor with C-terminal from the AChBP. Therefore, regions that had 
previously been in contact with the hydrophobic TM1-TM2 extracellular loop were 
replaced with the more hydrophilic regions found in the AChBP. The chimera also 
contained a signal sequence to enable secretion of the protein into the surrounding 
media, as well as an N-terminal FLAG epitope tag and a C-terminal His tag to allow for 
affinity purification.
The chimeric construct, the a7-Binding Protein (a7-BP), was incorporated into a 
pcDNA3.1 vector, and the vector was transformed into XL-1 blue supercompetent E.Coli 
cells using standard protocol and reagents (Stratagene). DNA was purified from these 
cells by DNA maxi-prep (Qiagen), and the presence of a7-BP cDNA was verified by 
restriction digest and agarose gel electrophoresis. The full length a7-BP chimera DNA 
including the FLAG and His-tagged regions was transfected into HEK-293 cells using 
the SuperFect reagent kit and standard protocol (Qiagen). Stable cell lines were 
developed and cultured. Culture medium was collected and any His-tagged proteins 
purified using Nickel-EDTA His-Select Columns (Sigma). Protein was eluted using 
imidazole, and then isolated from the eluent by filtration as described in Chapter 2 
(Materials and Methods). The protein yield was analyzed by Lowry assay (Sigma) and 
precast tris-HCl BioRad gels using standard methods.
Gel electrophoresis was performed under denaturing and non-denaturing (or 
native) conditions (Figure 4.2). The a7-BP protein was identified as about 30kD band 
under denaturing condition. The native gel showed a very faint band when the same 
amount of protein as denaturing gel was used (data not shown); therefore, the amount
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Figure 4.2: 10% Polyacrylamide Gels of a7-Binding Protein. Assembly of a7-Binding Protein (a7-BP) 
was determined using denaturing and native PAGE. The AChBP protein is added for comparison 
purposes, and concentrations of both proteins were normalized. The top gel shows the result of SDS 
PAGE (denaturing conditions) and the bottom gel shows the result of separation under non-denaturing 
conditions (PAGE). Gels were stained with coomassie blue stain (BioRad) (continued on the next page).
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Figure 4.2 (continued): The protein sample lanes are indicated by S, control by C, and the BioRad 
Kaleidoscope standard by Std. Denatured (SDS): Control sample is visualized at 30kD, and the AChBP 
protein at a region between 25 and 37kD as expected for the monomeric protein. 5X concentration of a7- 
BP protein (compared to the AChBP) was used for clear visualization. Non-denatured (no SDS): The 
AChBP protein migrated to a region equivalent to 150kD which is consistent with the predicted molecular 
weight of the pentameric AChBP. 2.5X concentration of a7-BP protein (compared to the AChBP) was 
used for visualization.
of sample loaded onto the gel was increased by 5-times to better identify the presence 
of the protein. The data from the denaturing gel indicates the synthesis of individual 
subunits, but does not indicate if the subunits assemble into a functional protein. The 
faint band in the native gel at an approximate MW ~ 150kD, likely corresponds to 
subunit assembly, although the broad diffused band may also suggest incorrect 
assembly. Possible explanations include: a) substitution of large regions of structure 
could have decreased the ability of the subunits to form correct contacts, or b) the large 
substitution might have decreased structural stability of the receptor for proper 
assembly and chimeric protein expression.
It took several transfections and follow up steps before we were able to see any 
protein on the gel electrophoresis. On average, Lowry assay showed that concentration 
of a7-BP protein was 1/5th to 1/3rd of control, the AChBP protein, which was not 
sufficient for binding assays. Since concentration of the a7-BP protein never improved 
after multiple tries, which can signal the failure of construct to produce adequate intact 
binding proteins, and the fact that chimeric constructs do not provide information 
regarding the receptor binding site, we decided to utilize the second approach or site- 
directed mutagenesis to explore the development of a serotonin-binding protein.
4.2.2 Site-directed Mutagenesis Approach
The cys-loop LGIC proteins are composed of five protein subunits that form a 
pentameric arrangement around a central pore. Each subunit consists of a large 
extracellular N-terminal domain, four transmembrane regions (M1-M4), and intracellular 
domain (1). The pore is primarily formed by the M2 helices of five subunits. The 
agonist binding site is located at the interface between two adjacent subunits in the 
extracellular domain; therefore, five potential binding sites exist in the pentameric
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receptors. Binding sites are composed of six loops of amino acids referred to as A-F 
(5,6).
Based on modeling and mutagenesis data, it appears that the ligands for LGIC 
receptors primarily utilize loops B, C, D, and E for their binding (5,126). Loop-A is 
hypothesized to play a role in initial ligand selection (99,128), and loop-F is suggested 
to be involved in the binding of all ligands by forming a flexible structure (129,130). 
While LGIC receptors have different amino acids, similarly positioned amino acids 
appear to play similar roles in interaction of the receptor with ligands (113,124). These 
binding loops are also key to transducing binding to conformational changes in LGICs 
that produce channel opening (3,6). A key receptor region in both binding of agonists 
and conformational change in the LGIC receptors is the C-loop. C-loop closure on 
binding of the ligand appears to be required for agonist action, and inhibition of this 
closing may contribute to the mechanism of competitive antagonists (5,126). The 
binding loop is highly variable between LGIC receptors that bind different classes of 
agonists (5,126).
It is known that the AChBP has a high affinity for nicotinic agonists (e.g. 
acetylcholine, nicotine, epibatidine), and antagonists (e.g. d-tubocurarine, bungarotoxin, 
conotoxin) (17,126). Previous data from our laboratory showed that the AChBP has a 
high affinity for serotonin antagonists (e.g. granisetron, d-tubocurarine, tropisetron, 
lerisetron, epibatidine), due to highly conserved residues in the B-and-D binding loops 
of both the AChBP and 5-HT3 receptor (113). On the other hand, the AChBP displays 
low affinity for serotonin agonists (e.g. serotonin, 2-Me-5HT, PBG, mCPBG) due to 
large sequence differences between the AChBP and 5-HT3 receptor in regions critical 
for agonist binding, particularly the C-and-E loops (113).
To convert the AChBP to a 5-HT3 binding protein, we systematically mutated 
those amino acids in the A, C and E loop that were known to be critical for recognition 
and binding of serotonin ligands to the appropriate 5-HT3 residues (113,124) using site- 
directed mutagenesis. Mutations were made as single and multiple site mutations with 
the goal of changing the selectivity of the AChBP to favor 5-HT3 ligands over nicotinic 
ligands.
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To determine if the binding characteristics of the mutated proteins were intact, we 
utilized scintillation proximity assay (SPA) as our standard method of evaluating binding 
interactions for the AChBP and AChBP-derivatives. This technique enables rapid 
evaluation of radioligand binding characteristics with minimal amounts of protein 
(113,117). SPA does not have a filtration step, which makes it easier to automate this 
technique and develop high-throughput assays. Since the receptor is covalently linked 
to the beads using an approach common to other biosensor surfaces, this approach 
also facilitates use of other surfaces including microcantilever (MC) (78,81) and surface 
plasmon resonance (SPR) sensors (77,80). [3H]-granisetron was selected as the 
radioligand for SPA since it binds to both the AChBP and 5-HT3 receptor (21,113). By 
monitoring changes in granisetron binding, the general structural impact of mutations on 
the binding site can be monitored. Previous modeling data from our laboratory 
predicted that the affinity of both the AChBP and 5-HT3 receptor for [3H]-granisetron 
would be similar since amino acid residues that are important in granisetron binding are 
conserved in both the AChBP and 5-HT 3 models (19,20,113,124).
It should be noted that the current project drew heavily on our laboratory’s 
experience and a wealth of prior structure and functional studies with: a) LGICs, b) 
extensive site-directed mutagenesis studies, c) biosensor experiences, and d) previous 
work and data collected for 5-HT3 receptors (19-21,113,124,131). This project is a 
highly ambitious protein engineering project since it is the first time that the AChBP has 
been investigated as a potential biosensor molecule for development of a soluble 
homolog of a non-nicotinic LGIC receptor. No binding protein has yet been developed 
with the ligand specificity of the 5-HT3 receptor despite the fact that the AChBP has 
been used extensively as a template to generate models of LGIC receptors, including 
the 5-HT3 receptor (9,93,115,124).
4.3 Selection of the AChBP Amino Acid Mutation
Alignment of the amino terminal sequence of the 5-HT3 receptor with the AChBP 
reveals significant sequence similarity (Figure 4.1). This similarity has been used for 
the development of several homology models of the 5-HT3 receptor biding site
(16,18,124). From homology models, ligand-docked models have been developed, and
63
both agonist and antagonist binding models have been proposed (8,115,127). Agonist 
models have focused on the full agonist serotonin (5-HT), and the partial-agonist m- 
chlorophenylbiguanide (mCPBG) (16,103,106,124,127). Antagonist models have 
focused on the classical antagonist granisetron which has one aromatic group and the 
non-classical antagonist Lerisetron with two aromatic groups (10,19,20,125,129).
Homology models of the 5-HT3 receptor show the binding site for agonist and 
antagonist is located at the interface between two adjacent subunits in the N-terminal, 
extracellular domain of 5-HT3 receptor (16,17). Therefore, five potential binding sites 
exist in the pentameric 5-HT3 receptors. Binding sites are composed of six loops of 
amino acids referred to as A-F. Each subunit contributes three loops on each of its two 
interfaces with loops A-C located on one interface (the ‘ + ’ face), and D-F located on 
the opposing interface (the ‘ -  ‘ face) (8,16). Key residues in these loops of the 
homomeric 5-HT3 receptor, as well as the AChBP mutants are described below and 
summarized in Table 4.1.
Loop-A
Residue N128 of the 5-HT3 receptor A-loop (equivalent to Y89 of the AChBP) 
has been proposed to be in the binding pocket (103,125). This residue is identified as a 
critical residue in ligand binding in the AChBP (99,128); however, data suggest that this 
residue is not a critical binding residue in the 5-HT3 receptor as N128 mutations do not 
significantly alter the binding efficacy of antagonists (129). It has been proposed that 
the A-loop might be involved in receptor assembly in 5-HT3 receptors since mutation of 
W121 and P123 results in receptors that do not reach the cell surface (132-134). It has 
also been suggested that the most critical A-loop residue is E129 (highlighted in Green 
in Loop-A, Figure 4.1), as it can modify both binding and function of the 5-HT3 receptor 
(22,134). The importance of E129 supports a role for loop-A binding and selectivity of 
ligands. For this study, N90 in loop-A of the AChBP was mutated to its equivalent E129 
residue in the 5-HT3 receptor. The mutation produces the N90E mutant, replacing 
asparagine (N) which has an uncharged R-group (side chain) with glutamate (E) which 
has a negatively charged R-group.
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Table 4.1: Mutants. The left-hand column shows the corresponding 5-HT 3 receptor amino acids in 
murine (m) or human (h), and the right-hand column shows the AChBP mutants.
Loop, m-or-h, 5-HT3 receptor amino acid AChBP residue, Mutation
Loop A (m), E129 N90E
Loop E (m), Y143 R104Y
Loop E (m), Y153 M114Y
Loop C (m), F226 T184F
Loop C (m), I228 S186I
Loop C (h), M228 S186M
Loop C (m), S233 A191S
Loop C (m), D229 / I230 C187D / C188I
Loop C (h), E229 / S230 C187E / C188S
Loop C (m), I230 /S231 C187I / C188S
Loop C (h), S230 /S231 C187S / C188S
Loop-B
The primary binding site for all LGIC and the AChBP ligands is the aromatic 
pocket of loop-B (16). The most important loop-B residue in the 5-HT3 receptor is W183 
(highlighted in Red in Loop-B, Figure 4.1). W183 has been extensively studied, and 
data has shown the critical nature of W183 for both ligand binding and function 
(130,135). In the AChBP, this residue is conserved as a tryptophan (W143).
Tryptophan is conserved in this position in all LGIC receptors except the GABA receptor 
which has a tyrosine (Y) in this position (128,136,137). Any mutation of W183 in the B- 
loop results in loss of ligand binding (130,135). Previous mutagenesis studies have 
shown that W183 forms a cation- n  bind with the primary amine (positive nitrogen) of 
LGIC ligands such as serotonin (124,130,138). Additional residues previously identified 
in this loop of the 5-HT3 receptor are H185, and D190 (16,138). The H185 residue is 
conserved in both the 5-HT3 receptor and the AChBP (H145). However, D190 
(aspartate) in the 5-HT3 receptor is equivalent to E149 (glutamate) in the AChBP
(20,127). Since both residues have hydrophilic amino acids and carry a negatively 
charged R-group, the properties of amino acids are conserved while the size is altered. 
The similarity of the B-loop in both the 5-HT3 and the AChBP indicate the importance of 
this loop for general ligand interactions, although it may play a less important role in 
ligand selectivity other than the preference of the receptor for a positively charged 
nitrogen group (127,138).
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Loop-C
This loop has been investigated intensely since little sequence homology is 
observed in loop-C between LGIC receptors that bind different classes of agonists
(18,124). In addition, this loop differs more substantially between species than any 
other loop of the 5-HT3 receptor (13,15,18). This suggests the C-loop may play a key 
role in ligand selectivity. Earlier studies attempted to find the residues responsible for 
the difference in the pharmacology of 5-HT3 receptor in murine and human using point 
mutations, but the results suggested that multiple regions of the binding site were 
involved (18,139). Since this is a highly variable region with little sequence homology 
between the AChBP and 5-HT3 receptor, the C-loop sequence of these receptors are 
difficult to align. A number of studies point to Y234 (highlighted in Green in Loop-C, 
Figure 4.1) in the 5-HT3 receptor as the most important residue involved in both ligand 
binding and function (124,140,141). It is suggested that upon binding of an agonist, the 
C-loop closes over the agonist, bringing Y234 into close contact with tryptophan residue 
183 (W183) in the aromatic pocket of B-loop (124,140). This tryptophan appears to 
produce one part of an aromatic binding domain that forms a key component of the 
ligand-binding domain in LGICs (5,6). The interactions of agonist with the C-loop are 
hypothesized to promote stability of this new conformation, thus providing energy for 
channel opening (6,126). Y234 of the 5-HT3 receptor appears equivalent to a tyrosine 
amino acid in the AChBP (Y192), which we used to loosely align the amino acid 
sequence of the AChBP and 5-HT 3 receptor (18,113). An interesting feature of this loop 
is the existence of proximal cysteines in the AChBP at positions 187/188 (C187/C188) 
that is missing in all the LGIC receptors except nACh receptor (98,99). These proximal 
cysteines produce a slight bulge in the C-loop, and are thought to confer the structural 
orientation that produce correct positioning of other residues (94,95,104).
It has been hypothesized that loop-C is also involved in the functional effects of 
binding of agonist versus antagonist, and may play a critical role in mediating the 
conformational change to the receptor in response to agonist (18,140). For agonist 
binding, the C-loop is thought to close more completely over the ligand compared to 
antagonists (18,130,140). The degree of C-loop closure may determine if a particular 
ligand is an antagonist, agonist or partial-agonist. Previous data from our laboratory
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showed that the AChBP has a low affinity for serotonin agonists and a high affinity for its 
antagonists (113). By mutating certain amino acids in the C-loop of the AChBP to 
appropriate 5-HT3 receptor residues, we hope to change the selectivity of the AChBP to 
closely resemble that of the serotonin receptor. This loop in particular may help explain 
why serotonin antagonists, but not agonists, generally bind to the AChBP. We chose to 
construct both single and double mutations to investigate if: a) our alignment of C-loop 
was correct, and b) to study the effect of removing the proximal cysteines of the AChBP 
on ligand binding.
Single mutations of C-loop amino acids are highlighted in blue or green in Figure 
4.1, and include F226, I228, D229, S233, and Y234:
a) F226 and S233 of the serotonin receptor are involved in agonist binding
(18,124); therefore, we mutated the equivalent AChBP amino acid (T184 and 
A191) to the homologous serotonin residue to produce the T184F and A191S 
mutations.
b) As mentioned, Y234 of the 5-HT3 receptor has an equivalent tyrosine amino 
acid in the AChBP (Y192), and these tyrosines were used to loosely align the 
amino acid sequence of the AChBP and 5-HT3 receptor. The AChBP 
proximal cysteines were aligned with D229 and I230 of the 5-HT3 receptor. 
Given the likely structural importance of this region of the C-loop and 
presence of a proline (P189) adjacent to the proximal cysteines of the 
AChBP, we decided to mutate the amino acids on each side of the proximal 
cysteines (AChBP amino acids S186 and P189) to their equivalent residues in 
the m5-HT3 receptor (I228 and S231 respectively). The resulting S186I and 
P189S mutations should produce alterations in the C-loop structure similar to 
that observed in the 5-HT3 C-loop. The C-loop of the 5-HT3 receptors from 
human and mouse differ in one position (I228), thus a human equivalent to 
the S186I mutation was also constructed to produce the S186M mutation.
Double amino acid mutations of the C-loop were also constructed. Since the C-loop 
contains structural differences (proximal cysteines/proline), deletion (one less residue in 
the 5-HT3 receptor), and several non-conserved residues, it presents a challenging 
engineering target. In addition, it is thought that all ligands (agonist or antagonist) bind
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to the C-loop, making it an important component of the binding site (18,124). In 
engineering this region, the following were considered key observations:
a) It has been suggested that the low affinity of the AChBP for serotonin agonists 
might be due to the presence of proximal cysteines (104,113,142); therefore, we 
decided to mutate those cysteine residues to their equivalent amino acids in the 
5-HT3 receptor to make the AChBP more like serotonin receptor and study the 
effect of cysteine removal on the AChBP affinity for serotonin agonist. Since 5- 
HT3 receptor residues equivalent to the C187 and C188 of the AChBP are also 
different between murine and human receptors, we also mutated the AChBP 
proximal cysteines to their equivalent in human receptor. The end result was 
production of C187D / C188I (mouse equivalent) and C187E / C188S (human 
equivalent) mutants.
b) The amino acid sequences of the AChBP and 5-HT3 receptors were loosely 
aligned, using tyrosine residues, which are hydrophobic amino acids. To verify 
this alignment, an alternate alignment was tested by aligning Y192 of the AChBP 
with A235 of the murine receptor, effectively shifting the alignment of the C-loop 
region by one residue. Based on this new alignment, the proximal cysteines of 
the AChBP were mutated to the alternate equivalent residues for the 5-HT3 
receptor in both murine and human receptors. These mutations correspond to 
C187I / C188S (murine) and C187S / C188S (human) mutants.
c) A third option which was not constructed was the potential deletion of V183 in the 
C-loop of the AChBP. Given other substantial structural and sequence 
differences, this would be unlikely to produce positive effects; however, it is 
possible this deletion could produce improvements if combined with the other 
mutations described above. This deletion mutation was thus considered 
premature until the effect of other mutations was considered.
Loop-D
Two aromatic residues have been shown to be important for agonist and 
antagonist interactions in the loop-D of 5-HT3 receptor, namely W90 and W95. W90 is 
critical for ligand binding, while W95 affects cell surface expression (129,130). Both of
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these residues have an equivalent tryptophan amino acid in the AChBP (W53 and W58) 
that are also important in binding (101,143), indicating that this position is functionally 
similar in both receptors. The D-loop of 5-HT3 receptor and the AChBP are highly 
homologous in this region, with only small differences observed and critical residues 
identical between the two proteins (101,130,144).
Loop-E
A homologous glycine (G148) was used to align the residues of 5-HT3 receptors 
and the AChBP since glycine likely produces a sharp and very tight p-turn in the middle 
of the loop. A glycine residue cannot be replaced as any mutation of this amino acid 
would typically produce structural changes. Different studies of the 5-HT3 receptor have 
shown that Y143, G148, V150, and Y153 are likely important for granisetron binding to 
serotonin receptor, and mutation of G148 and V150 completely abolished granisetron 
binding (21). Both of these residues have an equivalent glycine and valine amino acid 
in the AChBP (G109 and V111). Two tyrosine residues of 5-HT3 receptor, Y143 and 
Y153, have been shown to be involved in receptor function (140), and Y153 also has a 
role in ligand binding (141). It is suggested that as the C-loop closes over the agonist, 
these tyrosines, especially Y153, interacts directly with the ligand and stabilizes the new 
position of the ligand (21,140). We decided to mutate the R104 and M114 residues 
from loop-E of the AChBP to its equivalent Y143 and Y153 residues in 5-HT3 receptor, 
resulting in R104Y and M114Y mutants.
Loop-F
In the AChBP crystal structure, the F-loop region was poorly resolved (99). Early 
functional studies suggested loop-F had two distinct regions: the upper region that lines 
the binding pocket and the lower region that acts as a link between ligand binding and 
channel opening (115). Several studies suggested loop-F may play a role in locking the 
agonist molecule into the binding site, and thus resulting in a local structural 
rearrangement (111). To date, mutational information suggests that loop-F is the most 
flexible region in the receptor during activation, and that it is involved in ligand binding 
and activation (98,111).
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4.4 Methods
Once the AChBP amino acids for single-site and double-site mutations were 
determined as explained above, oligonucleotides were created to generate mutations, 
and mutant receptors constructed as described in the Materials and Methods, Chapter 
2. Oligonucleotides were designed using the DNA Strider program, and custom 
designed DNA oligonucleotides corresponding to the desired mutations were ordered 
through The Midland Certified Reagent Co., Inc. Using these oligonucleotides, 
mutations were constructed with the QuickChange II Site-Directed Mutagenesis kit 
(Stratagene) using the standard methods with the following modifications: 50 ng of the 
AChBP DNA and a pair of designed oligonucleotides for a specific mutation were used 
for each Polymerase Chain Reaction (PCR). The PCR machine was programmed for 
18 cycles of denaturation for 1-minute at 95 °C, annealing for 1-minute at 60-65 °C (it 
was always 10 °C less than oligo’s temperature), and extension for 9-minutes at 68 °C. 
PCR products were treated with 1- ^l of DpnI restriction enzyme (20,000 units/ml), and 
incubated for 1-hour at 37 °C to digest methylated parental DNA.
XL-1 blue supercompetent E.Coli cells were transformed with 4- ^l of DpnI- 
treated mutant DNA using standard protocol and reagents (Stratagene). DNA was 
purified using Mini-prep and Maxi-prep DNA purification systems (Qiagen). The 
presence of the coding region (insert) was verified by restriction digest and agarose gel 
electrophoresis. The verified mutant DNA was sent to Sequetech Corp. Mountain View, 
CA (http://datasytem.sequetech.com) for commercial sequencing to verify only desired 
mutations had been incorporated into the coding region.
Once it was verified that the AChBP residues were correctly mutated, mutant 
DNA was transfected into HEK-293 cells to develop stably transfected cell lines that 
secrete mutated AChBP protein into the extracellular medium. The mutant DNA was 
then purified, and analyzed by Lowry assay and polyacrylamide gel electrophoresis.
The mutant protein was identified as the 150kD band under non-denatured conditions, 
and it was concluded that the mutant protein was expressed as a pentamer (data not 
shown). The mutant DNA was then stored, and pharmacologically characterized using 
SPA as explained in Chapters 2-and-3.
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4.5 Functionality of the AChBP Mutants
To explore the binding characteristics of the AChBP mutants, mutant proteins 
were immobilized on the SPA beads under optimized conditions as described in 
Chapter 3 (0.2 mg/ml beads, 5 mg/ml BSA and 10 nM AChBP). The 6X His tag on the 
C-terminal of the mutated protein binds to copper on the SPA beads resulting in 
immobilization of the mutated protein on the bead surface. Different concentrations of 
radioligand, [3H]-granisetron, were incubated with the protein/bead complex, and the 
fraction of bound radioligand was determined by a scintillation counter after a 2-hour 
incubation period. Nonspecific binding was determined in the presence of 1.0 M 
acetylcholine, and was subtracted from total binding to give the specific binding of [3H]- 
granisetron to the AChBP.
To test the functionality of mutated proteins and evaluate them for development 
of a soluble biosensor protein that mimics the 5-HT3 receptor, we explored the ability of 
mutated proteins to interact with nicotinic and serotonergic ligands in competition with 
[3H]-granisetron using SPA assay. In these experiments, we assayed the following 
ligands: nicotinic receptor agonist acetylcholine; nicotinic receptor antagonist d- 
tubocurarine (dTC); serotonin agonist, seroton; 5-HT3 receptor partial-agonists m- 
chlorophenylbiguanide (mCPBG) and 2-Methyl-serotonin (2-Me-5HT); and the 5-HT3 
receptor antagonist granisetron.
The data in this section is divided into: a) direct binding of the AChBP mutants 
with [3H]-granisetron, and b) competition binding assays using the nicotinic and 
serotonergic ligands described above. Both assays utilized SPA as the biosensor 
platform, and data for both assays are listed on Table 4.2.
4.5.1 The AChBP Mutant Binding Assay
For evaluation of [3H]-granisetron binding, 10 nM of mutant protein, 5mg/ml of 
BSA, and 0.2 mg/ml of SPA beads per sample well were used. [3H]-granisetron 
concentrations were varied between 0.00-and-300 nM. Similar to conventional binding 
assays, the equilibrium binding constant or dissociation constant (Kd) for the radioligand 
[3H]-granisetron was determined from a plot of radioligand concentration vs. fraction
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bound. Data was analyzed using GraphPad Prism software. The Kd value was 
calculated using the simple one-site binding model:
Y = Bmax * X / Kd + X
where X is the radioligand concentration, Y is the amount bound in counts per minute 
(CPM), Kd is the binding affinity, and Bmax is the calculated maximal binding.
4.5.2 The AChBP Mutant Competition Assay
The radioligand [3H]-granisetron was utilized as the radioligand in competitive 
binding assays. For competition experiments, the [3H]-granisetron concentration was 
fixed at a concentration equal to the Kd for granisetron. In addition, 10 nM of mutant 
protein, 5mg/ml of BSA, and 0.2 mg/ml of SPA beads were added to each sample well. 
At least 8 concentrations of competitor ligand in 3-fold increasing concentrations were 
used to acquire the final data. Competing ligand was added prior to addition of the 
radioligand, and was incubated with mutant protein and SPA beads for 1-hour at ~21 °
C (room temperature). Once radioligand was added, the combined mixture was 
incubated at room temperature on a shaker (with low speed) for a minimum of 2-hours 
before the radioactivity level was measured and counted by the scintillation counter.
Competition assays determine the IC50 value (in nM or ^M), which represents the 
concentration of a ligand/drug that is required for 50% inhibition. The IC50 of cold 
ligands for the inhibition of granisetron was determined by using the sigmoidal dose- 
response equation and GraphPad Prism software:
Y = Bmax / (1 + 10 ([log(IC50)-X] * n) ) 
where X is the logarithm of the concentration of cold ligand, Y is the response in counts 
per minute (CPM), and n is the Hill-slope.
4.6 Results
The equilibrium binding constant or dissociation constant (Kd) for the radioligand 
[3H]-granisetron was first determined for all the mutants. The Kd value determined for 
each mutant binding protein was then used as the fixed [3H]-granisetron concentration 
for competition / inhibition assays. This section is divided into two major subsections: a) 
mutants that did not interact with granisetron, and b) mutants that interacted with
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granisetron and different ligands. Each subsection will review the data presented, 
propose possible explanation and an overall conclusion. Data for all the assays are 
listed in Table 4.2 and Figure 4.3.
4.6.1 Mutants that Did Not Interact with Granisetron
Although it is ideal to have positive results in any type of experiment, especially 
mutagenesis studies, negative results are equally important since they demonstrate 
involvement and/or role of certain residues in an interaction. In general, mutagenesis 
data that shows a decrease in affinity suggests that the mutated residue is involved in 
the interaction of the receptor with the ligand.
A-loop Mutation (N90E):
As mentioned before, A-loop is considered a rigid loop which contains conserved 
residues. In the A-loop, the E129 residue of the 5-HT3 receptor (5-HT3R-E129) is 
involved in binding of both agonists and antagonists (124,134). Under normal 
conditions, serotonin does not bind to the nACh receptor; however, mutation of E129 
residue of 5-HT3 receptor to its equivalent in the nACh receptor leads to binding of 
serotonin to the nACh receptor. This suggests that E129 is important for ligand 
selectivity. Mutation of the AChBP-N90, which is the counterpart to 5-HT3R-E129 (in 
both mouse and human), was intended to increase selectivity of the AChBP for 
serotonin ligands. Asparagine (N) is a hydrophilic residue with an uncharged R group, 
and glutamate (E) is also a hydrophilic residue but with a negatively charged R group. 
Binding data for [3H]-granisetron showed a significant decrease in Kd for granisetron 
(>300 nM), thus preventing analysis of other compounds using competition assays 
(Table 4.2). This result signals importance of this A-loop residue for binding of 
granisetron to the AChBP. We did not test this mutant with the remaining ligands as 
without [3H]-granisetron binding we would not have been able to monitor any change or 
compare results of ligand interaction in mutant receptors versus wild type. Previous 
data from our lab proposed that A-loop in 5-HT3 receptor might serves as a pre-binding 
site to facilitate ligand entry by allowing antagonists to bind to A-loop, followed by a shift
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Table 4.2: Mutant Data. The AChBP and mutants are listed on the left-hand column, and ligands used 
are listed on the top row. The result for 95% Confidence Interval (Conf.Inter.) is the top number, and Kd 
or IC50 in nM or pM is the second number in the result section. The abbreviations used in this table and 
their meaning are as follow: SE (standard error); Kd > 300 nM (maximum granisetron used for this 
experiment was 300 nM, and Bmax could not be calculated to calculate the Kd); ND (not determined due to 
high Kd for granisetron); NI (inhibition did not reach 50% using the highest concentration of ligand); ** 
(inhibition reached 50% or more using the highest concentration of ligand; however, the available data 
was insufficient. Estimated value reported here was obtained by constraining top and bottom of the curve 
between 0-and-1). Second table shows literature values reported by Schulte et al. (21), which lists Kd 
and IC50 in nM or pM for 5-HT3 receptor.
Name Granisetro
n
95%
Conf.Inter. 
Kd ± SE 
(nM)
dTC
95%
Conf.Inter.
(IC50)
nM
ACh
95%
Conf.Inter.
(IC50)
pM
5HT
95%
Conf.Inter.
(IC50)
pM
mCPBG
95%
Conf.Inter.
(IC50)
pM
2-Me-5HT
95%
Conf.Inter.
(IC50)
pM
AChBP 10.0 -  28.8 
19.4 ± 4.5
9.95 - 20.9 
(14.4)
2.30 - 4.32 
(3.16)
442 - 927 
( 640)
253 - 469 
(344)
33.7 - 49.8 
(41.0)
N90E (A) > 300 nM ND ND ND ND ND
R104Y (E) > 300 nM ND ND ND ND ND
M114Y (E) > 300 nM ND ND ND ND ND
T184F (C) 12.1 -  39.5 
25.8 ± 6.5
NI
( > 300)
1.21 - 4.54 
(2.34)
NI
( > 3000)
NI
( > 3000)
1498-3701 
( 2355) **
S186I (C) 56.2 - 106 
81 ± 12
NI
( > 300)
9.31 - 19.2 
(13.4)
623 - 1093 
(825)
536 - 1071 
(758)
54.2 -  87.0 
(68.7)
S186M (C) 15.0 -  45.2
30.1 ± 7.2
NI
( > 300)
3.85 -  7.41 
(5.34)
NI
( > 3000)
NI
( > 3000)
1656-4204 
( 2638) **
P189S (C) 63.4 - 101 
82.3 ± 9.1
88.6 - 224 
(141)
4.89 -  12.7 
(7.90)
1614-2678 
(2079) **
1445-2252 
(1804) **
327 - 518 
(412)
A191S (C) > 300 nM ND ND ND ND ND
C187D/C188I > 300 nM ND ND ND ND ND
C187E/C188S 48.2 -  93.0 
70.6 ± 11
34.5 -  54.6 
(43.4)
25.6 -  68.1 
(41.7)
1648-2792 
( 2145) **
321 - 514 
(407)
83.8 - 145 
(110)
C187I/C188S 8.85 -  15.9 
12.4 ± 1.8
57.6 - 153 
(93.8)
5.26 -  11.6 
(7.82)
146 - 510 
(273)
136 - 328 
(211)
90.1 - 173 
(125)
C187S/C188S 45.8 -  72.3 
59 ± 6.4
56.3 - 132 
(86.2)
15.9 -  50.8 
(28.4)
1350-2335 
(1775) **
455 - 880 
(633)
141 - 256 
(190)
5-HT3 0.98 ± 0.12 (12) Not available (0.148) (0.006) (0.3)
of ligand to D-loop, and its final association with the B-loop (113,124). It is possible that 
mutation of A-loop in the AChBP blocked ligand entry since the glutamate (E) residue is 
large in size and it might not have left enough space for the ligand to bind, or the 
structural change of the receptor due to the mutation affected or prevented residue 
interactions.
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E-loop Mutations (R104Y and M114Y):
In the E-loop, Y143 of 5-HT3 receptor is involved in agonist binding, and Y153 is 
selective for binding of agonist over partial-agonist, mCPBG (21). The R104Y and 
M114Y mutations produce the AChBPs that are equivalent to 5-HT 3R-Y143 and Y153 
respectively (in both mouse and human). These mutations were intended to increase 
selectivity of the AChBP for the serotonin agonist. Arginine (R) is a hydrophilic residue 
with a positively charged R group, methionine (M) is a hydrophobic residue with a 
nonpolar R group, and tyrosine (Y) is a hydrophobic residue with an aromatic R group. 
Binding data showed a significant decrease in granisetron affinity (>300 nM) for both 
mutated AChBPs, thus preventing analysis of other compounds using competition 
assays (Table 4.2). The results indicate that the original residues in the E-loop are 
important for binding of granisetron to the AChBP. It is possible that mutation of E-loop 
in the AChBP blocked ligand entry since the tyrosine residue contains an aromatic ring 
which is large in size and it might not have left enough space for the ligand to bind, or 
the structural change of the receptor due to the mutation affected or prevented residue 
interactions. We did not test these mutants with the remaining ligands as without [3H]- 
granisetron binding we would not have been able to monitor any change or compare 
results of ligand interaction in mutant receptors versus wild type.
C-loop Mutations (A191S and C187D/C188I):
The C-loop is proposed to be involved in ligand selectivity (18). This loop has the 
most variable residues and is very different between the AChBP and serotonin receptor
(18,124). In addition, proximal cysteines are present in the C-loop of the AChBP, but 
not in the serotonin receptor (18,113). In the C-loop, the S233 residue of the 5-HT 3 
receptor (5-HT3R-S233) is involved in binding of both agonists and antagonists. The 
AChBP-A191S mutation, which is equivalent to 5-HT3R-S233 (in both mouse and 
human), was intended to increase selectivity of the AChBP for serotonin ligands. In 
addition, the double mutation of AChBP-C187 and AChBP-C188 to their equivalent in 
the serotonin receptor (C187D/C188I in mouse, or C187E/C188S in human) was 
intended to remove the proximal cysteines to study their effect on the function of the C- 
loop. Alanine (A) and isoleucine (I) are hydrophobic residues with a nonpolar R group;
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serine (S) and cysteine (C) are hydrophilic residues with an uncharged R group; and 
aspartate (D) is also a hydrophilic residue, but with a negatively charged R group. 
Binding data for [3H]-granisetron showed a significant decrease in Kd for granisetron 
(>300 nM), in both the single mutation (A191S), and double mutations (C187D/C188I), 
thus preventing analysis of other compounds using competition assays (Table 4.2). The 
results signal importance of the original residues for binding of granisetron to the 
AChBP. In addition, since the C-loop is the most variable loop between the AChBP and 
5-HT3 receptor, the results might indicate that these mutations have shifted the C-loop 
alignment, or that the C-loop alignment is not correct. We did not test these mutants 
with the remaining ligands as without [3H]-granisetron binding we would not have been 
able to monitor any change or compare results of ligand interactions in mutant receptors 
versus wild type. Since granisetron did bind to the C187E/C188S mutation, the result of 
this mutant will be discussed in the next section.
Conclusion:
All of our mutants produced protein which were tested and identified as 
assembled protein. However, the five mutants mentioned above did not result in 
binding of granisetron to the AChBP which signals importance of those residues in 
binding of granisetron to the AChBP. As mentioned previously, we did not test these 
mutants with the remaining ligands as without [3H]-granisetron binding we would not 
have been able to monitor any change or compare results of ligand interactions in 
mutant receptors versus wild type.
Based on previous results from our lab, serotonin antagonists bind tightly to the 
AChBP, whereas the opposite is true for serotonin agonists (21,113). Since all of the 
mutations in this study are ‘substitution’ mutations, a decrease in affinity means the 
ligand does not interact similarly with the wild-type as it does with the mutant receptor. 
The results could be due to the size of substituted residue, meaning the new residue did 
not leave enough space for the ligand to bind, or that it completely blocked ligand entry. 
It is also possible that a structural change of the receptor due to the mutation affected or 
prevented residue interactions.
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4.6.2 Mutants that Interacted with Granisetron and Different Ligands
All the mutants that interacted with granisetron were in the C-loop (Table 4.2 and 
Figure 4.3). Mutations were selected to try to increase binding affinity of the serotonin 
agonist and partial-agonists for the receptor. In general, mutations result in a change of 
affinity. Since all the mutations in this study were ‘substitution’ mutations, a positive 
result can mean a substantial, small or no affinity increase when a mutant data is 
compared with the wild-type. In addition, small improvements or no change in the 
affinity of the mutated receptor for a serotonin ligand signals proper alignment of the C- 
loop between the AChBP and serotonin receptors.
C-loop Mutation T184F:
This mutation replaced a threonine (T) residue that contains a hydrogen bond with 
phenylalanine (F) which has an aromatic ring and is a larger residue compared to T. 
Results show that the mutation did not affect granisetron and ACh binding; however, it 
decreased the binding affinity of the antagonist dTC as well as serotonin agonist 5- 
HTand partial-agonists mCPBG, for the mutated receptor. Results for the T184F 
mutation indicate that the T residue is involved in binding of dTC, 5-HT and mCPBG to 
the AChBP (Figure 4.3). It is possible that the large size of the substituted residue (F) 
makes it impossible for certain ligands to interact with the mutated receptor, or that a 
structural change of the receptor due to the mutation affected or prevented residue 
interactions. Data might also indicate that the T residue is involved in selective 
interaction of 2-Me-5HT with the AChBP since the other partial-agonist did not interact 
with the receptor. This discrepancy might be due to a structural alteration in the binding 
site caused by the mutation. The 95% confidence interval of the AChBP for 2-Me-5HT 
did not overlap with the mutated receptor, signaling a significant difference between the 
mutated receptor and the AChBP (Table 4.2). This data is verified by decreased affinity 
of the 2-Me-5HT ligand for the receptor due to the mutation.
In addition, results indicate that antagonists dTC and granisetron might interact 
differently with this region since the affinity of granisetron had decreased for the 
mutated receptor, but binding of granisetron was not altered by this mutation. The 
difference in the binding site interaction between these two antagonists cold be the
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Figure 4.3: Results of Binding Assays for Different Mutants. This figure was developed using original 
data from Table 4.2. All the mutant data were normalized using the AChBP results.
result of a different positioning of dTC in the binding site, resulting in a lack of interaction 
between dTC and the mutated receptor. Data also show that ACh binding is present, 
which indicates that the basic structure of the C-loop is not affected by the mutation.
In order to have a functional receptor, hydrogen bonding properties are needed. An 
option to improve the results of this mutation might be a substitution of the serine (S) 
residue of the 5-HT3 receptor (5-HT3R-S227), which is capable of hydrogen bonding, 
instead of F226. This would mean that the residues have to shift one position to align 
the AChBP-T184 with 5-HT3R-S227, which would indicate that the current alignment 
used to design the mutants might not be correct.
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C-loop Mutation S186I (mouse equivalent):
This mutation replaced serine (S) which is hydrophilic and capable of forming a 
hydrogen bond with isoleucine (I), which is hydrophobic and larger in size when 
compared to S. Results show that the mutation decreased the binding affinity of the 
antagonist dTC for the mutated receptor, which indicates that the S residue is involved 
in binding of dTC to the AChBP (Figure 4.3). However, binding of granisetron was not 
altered by this mutation which indicates antagonists dTC and granisetron might interact 
differently with this region. The difference in binding site interaction between the two 
antagonists could be the result of a different positioning of dTC in the binding site.
The 95% confidence interval of the mutated receptor for granisetron, ACh, 
mCPBG and 2-Me-5HT did not overlap with the wild-type receptor, signaling significant 
difference between the mutated receptor and the AChBP (Table 4.2). This data is 
verified by decreased affinity of above mentioned ligands for the receptor due to the 
mutation. In addition, results show that ACh binding is present, although the mutation 
has decreased affinity of ACh for the receptor, which indicates the basic structure of the 
C-loop was not affected by the mutation. Taken together, these effects seem to 
suggest that this residue (S) is not very important to binding as the mutation itself is a 
substantial change (from hydrogen bond to lack of hydrogen bond); however, the 
mutation did not alter the binding affinity of either nicotinic or serotonergic ligands 
drastically. This could possibly be another alignment problem.
C-loop Mutation S186M (human equivalent):
This mutation replaced serine (S) which is hydrophilic and contains a hydrogen 
bond with methionine (M) which is hydrophobic and larger in size compared to S. 
Results show that the mutation did not affect granisetron and ACh binding; however, it 
decreased the binding affinity of the antagonist dTC as well as the serotonin agonist 5- 
HT and partial-agonists mCPBG, for the mutated receptor (Figure 4.3). Results for the 
S186M mutation indicate that the S residue is involved in binding of dTC, 5-HT and 
mCPBG to the AChBP. It is possible that the mutation blocked ligand entry since the 
substituted M residue is large in size and it might not have left enough space for the 
ligand to bind, or that the structural change of the receptor due to the mutation affected
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or prevented residue interactions. Data might also indicate that the S residue is 
involved in a selective interaction of 2-Me-5HT with the AChBP since the other partial- 
agonist did not interact with the receptor. This discrepancy might be due to a structural 
alteration in the binding site caused by the mutation. The 95% confidence interval of 
the AChBP for 2-Me-5HT did not overlap with the mutated receptor, signaling a 
significant difference between the mutated receptor and the AChBP (Table 4.2). This 
data is verified by a decreased affinity of the 2-Me-5HT ligand for the receptor due to 
the mutation.
In addition, results indicate that antagonists dTC and granisetron might interact 
differently with this region since the affinity of granisetron had decreased for the 
mutated receptor, but binding of granisetron was not altered by this mutation. The 
difference in the binding site interaction between the two antagonists could be the result 
of a different positioning of dTC in the binding site. Since ACh binding is present, 
although the mutation decreased affinity of ACh for the receptor very little, it indicates 
that the basic structure of the C-loop was not affected by the mutation. Comparison of 
results for S186I and S186M indicate similar effects for both receptors which might 
suggest an alignment problem.
C-loop Mutation P189S:
This mutation replaced proline (P) which is hydrophobic with serine (S) which is 
hydrophilic and is capable of forming a hydrogen bond. Proline has a distinctive cyclic 
structure that causes it to have an exceptional conformational rigidity compared to other 
amino acids (1). P is commonly found in protein turns where the polypeptide chain 
reverses its overall direction. Results show that the mutation did not affect binding and 
interaction of the antagonist dTC, which indicates that the P residue is not involved in 
binding of dTC to the AChBP. In addition, data also show that this mutation resulted in 
the highest affinity decrease of any mutant for both antagonists at the same time (Figure 
4.3). Since the general goal of the mutation was to decrease affinity of serotonin 
antagonists and ACh, and increase affinity of serotonin agonists for the receptor, these 
results indicate involvement of the S residue in decreasing affinity of serotonin 
antagonists for the AChBP.
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The 95% confidence interval of the mutated receptor for none of the ligands 
overlapped with the wild-type receptor, signaling a significant difference between the 
mutated receptor and the AChBP (Table 4.2). This data was verified by decreased 
affinity of all the ligands for the receptor. In addition, although P changed the structure 
of C-loop profoundly, data shows that ACh binding was present, and that the mutation 
had decreased affinity of ACh for the receptor. This result indicates that the basic 
structure of C-loop was not affected by the mutation.
C-loop Mutations C187E/C188S (human equivalent):
This mutation replaced cysteine (C) which is a hydrophilic residue and contains 
an uncharged R group, with serine (S) which is from the same group as C, as well as 
glutamate (E) which is also hydrophilic but contains a negatively charged R group. The 
main goal of this mutation was to replace the proximal cysteines of the AChBP (which is 
absent in serotonin receptor) with its equivalent residues in the human 5-HT3 receptor, 
and study its effect on the structure of the receptor as well as binding and interaction of 
the mutated receptor with different ligands.
Results show that mutation did not affect binding and interactions of antagonists 
granisetron or dTC with the receptor, although it decreased affinity of both ligands for 
the mutated receptor, which indicates proximal cysteines were not involved in binding of 
granisetron or dTC to the AChBP (Figure 4.3). This is the first time it was shown that 
the proximal cysteines could be substituted with other residues and result in a 
functioning receptor.
The 95% confidence interval of the mutated receptor for the ligands did not 
overlap with the wild-type receptor, signaling a significant difference between the 
mutated receptor and the AChBP (Table 4.2). This data was verified by decreased 
affinity of all ligands for the receptor. Results also showed that ACh binding was 
present, and that the mutation decreased affinity of ACh for the receptor, indicating that 
the basic structure of the C-loop was not affected by the mutation.
The general goal of the mutation was to decrease affinity of serotonin 
antagonists and ACh, and increase affinity of serotonin agonists for the receptor. Both 
C187E/C188S and P189S mutations showed a decrease in affinity of ligands for the
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receptor, which might suggest that the S residue was involved in this process. In 
addition, the C187D/C188I mutation (mouse equivalent) did not yield any result; 
however, ligands interacted with the C187E/C188S mutant (human equivalent). 
Comparing the results of two double mutants might indicate that at position 188, the C- 
to-S mutation did less damage than the C-to-I mutation since the C-to-E and C-to-D at 
position 187 were similar (both are hydrophilic and have a negatively charged R group). 
This would support the idea that the original alignment might be wrong.
C-loop Mutations C187I/C188S (mouse equivalent, alternate alignment):
Results of single mutations indicated that in order to have a functional receptor, 
hydrogen bonding properties were needed, and that the S residue was involved in 
increasing the affinity of ligands for the receptor. And results of double mutations 
showed that proximal cysteines could be substituted with other residues and yield a 
functional receptor, and that most likely, the original alignment used to design the 
mutants might be wrong. We decided to shift the alignment one residue (position) so 
the proximal cysteines could be substituted with new residues capable of hydrogen 
bonding. This new alignment produced a C187I/C188S double mutation which is 
explained in this section. The mutation replaced the cysteine (C) with serine (S), both of 
which are from the same group of hydrophilic residues that contain an uncharged R 
group and can form a hydrogen bond. The other substituted residue was isoleucine (I) 
which is hydrophobic and nonpolar (Table 4.3).
Results showed that the mutation did not affect binding and interaction of 
antagonists granisetron or dTC with the receptor, which indicates proximal cysteines 
were not involved in binding of granisetron or dTC to the AChBP (Figure 4.3). Data 
indicates a decreased affinity of dTC for mutated receptor when compared to the 
AChBP, and the 95% confidence interval of mutant did not overlap with the AChBP 
indicating a significant difference between them (Table 4.2). Results might indicate a 
difference in binding site interaction between the two antagonists, which most likely 
could be the result of a different positioning of granisetron and dTC in the binding site. 
Since ACh binding was present, although the mutation has decreased affinity of ACh for
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Table 4.3: Alternative Sequence Alignment of the C-loop for the AChBP and 5-HT3 
Receptors. Aligned sequences in the C-loop: Lymnaea stagnalis AChBP (AChBP), murine 5-HT3 
receptor (m5-HT3A R), human 5-HT3 receptor (h5-HT3A R), and suggested alternative alignment (Alt).
AChBP S V T Y S C C P E A Y E D V
m5-HT3 E - F S I D I S N S Y A E M
h5-HT3 E - F S M E S S N S Y A E M
Alt: m5-HT3 E F S I D I S N S Y A E M -
Alt: h5-HT3 E F S M E S S N S Y A E M -
the receptor, it indicates that the basic structure of the C-loop was not affected by the 
mutation.
The general goal was to decrease affinity of serotonin antagonists and 
acetylcholine for the receptor through mutation. The 95% confidence interval of the 
mutated receptor for dTC and ACh did not overlap with the wild-type receptor, signaling 
a significant difference between the mutated receptor and the AChBP (Table 4.2). This 
data was verified by the decreased affinity of the ligands for the mutated receptor. It 
was also a general goal to increase receptor affinity for serotonin agonists and partial- 
agonists. IC50 data verifies increased affinity of 5-HT and mCPBG for the mutated 
receptor, when compared to other receptors; however, data shows a decreased affinity 
of partial-agonist mCPBG for the receptor when compared to the wild-type. The 95% 
confidence interval of the mutated receptor for 2-Me-5HT ligands did not overlap with 
the wild-type receptor, signaling significant difference between the two (Table 4.2).
Since the structural make up of partial-agonists are different, it is possible that the 
structural change of the receptor due to the mutation affected residue interactions, 
resulting in a low affinity of the 2-Me-5HT ligand for the mutated receptor when 
compared to the AChBP. It is interesting to note that the highest affinity for this ligand 
was observed in the S186I mutant, and although the IC50 data for C187I/C188S showed 
a lower affinity for 2-Me-5HT ligand when compared to the wild-type receptor, in reality, 
it was the third highest affinity after S186I and C187E/C188S. Taken together, data 
showed the proximal cysteines were not involved in ligand binding and could be 
substituted to yield a fully functional receptor, which indicates that the new alignment 
might be an improved alignment.
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C-loop Mutations C187S/C188S (human equivalent, alternate alignment):
Both original (C) and mutated (S) amino acids belong to the same group whose 
members have hydrophilic residues that contain an uncharged R group. Data for this 
mutant was very similar to the first functional double mutation C187E/C188S. Results 
showed that the mutation did not affect binding and interaction of antagonists 
granisetron or dTC with the receptor, although it decreased affinity of both ligands for 
the mutated receptor, which indicates that the proximal cysteines were not involved in 
binding of granisetron or dTC to the AChBP (Figure 4.3). Data also showed that ACh 
binding was present, although the mutation decreased affinity of ACh for the receptor, 
indicating that the basic structure of the C-loop was not affected by the mutation.
Except for mCPBG, the 95% confidence interval of the mutated receptor for none 
of the ligands overlapped with the wild-type receptor, signaling a significant difference 
between the mutated receptor and the AChBP (Table 4.2). This data was verified by 
decreased affinity of the ligands for the mutated receptor.
Conclusion A: Antagonist Binding Site
Granisetron and d-Tubocurarine (dTC) are antagonists for both the AChBP and 
5-HT3 receptors, and the goal of the mutations was to decrease the affinity of the 
mutants for serotonin antagonists. N90E (loop-A), R104Y and M114Y (loop-E), and 
A191S (loop-C) did not show any binding to antagonist granisetron, indicating that 
amino acids N, R, M and A were involved in binding of the AChBP to granisetron. It is 
possible that the structural change of the receptor due to the mutation affected residue 
interactions, resulting in lack of interaction between granisetron and the mutated 
receptors. Data for mutants that were tested showed a general decrease in affinity of 
granisetron for the mutated receptors, and the majority of mutants did not show any 
overlap in their 95% confidence intervals with the AChBP, signaling a significant 
difference between these mutant receptors and the wild-type (Table 4.2).
Mutants that showed the least affinity for granisetron, P189S and S186I, were the 
two residues on either side of the AChBP proximal cysteines. In addition, the third 
mutant with the least affinity was C187E/C188S, which was a mutant with no proximal 
cysteines. Taken together, it seems that the AChBP proximal cysteines might be
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involved in high affinity of the AChBP for serotonin antagonist, granisetron. And that 
substitution of proximal cysteines in the AChBP with its corresponding residues in the 5- 
HT3 receptor, as well as mutation of one residue on either side of the proximal cysteines 
might result in decreased affinity of granisetron for the AChBP.
The only mutation that showed increased affinity of granisetron for the receptor, 
C187I/C188S, was designed by using a new alignment, and the Kd value of this mutant 
was close to the AChBP. This data suggests: a) possibility and probable validity of a 
new alignment between the AChBP and 5-HT3 receptor since the mutation produced an 
active protein with similar functional characteristic as the AChBP, and b) proximal 
cysteines can be replaced with different residues, namely isoleucine (I) and serine (S), 
without inactivating the receptor protein. This is the first time it has been shown that the 
proximal cysteines can be substituted with other residues and result in a functioning 
receptor.
In the C-loop, mutants T184F, S186I and S186M did not show any binding to 
antagonist dTC, indicating that amino acids T and S are involved in binding of the 
AChBP to dTC. It appears antagonists dTC and granisetron interact differently with this 
region since binding of granisetron was not altered by this mutation. The difference in 
binding site interaction between the two antagonists could be the result of a different 
positioning of dTC in the binding site.
The general result for the rest of mutations showed decreased affinity of mutated 
receptors for dTC. None of the mutations showed any overlap in their 95% confidence 
intervals for dTC with the AChBP, signaling a significant difference between these 
mutant receptors and the wild-type (Table 4.2). Among these mutants, the highest 
affinity decrease for dTC was 8.8 fold (displayed by P189S), which was considered 
moving in the right direction; however, the difference was not very significant from the 
AChBP. The lack of any large change in binding affinity showed that there was little 
structural change at the binding site due to the mutation, and that the substituted 
residues were important in the interaction of the ligand, dTC, with the 5-HT3 receptor.
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Conclusion B: Agonist Binding Site
Acetylcholine (ACh) is an agonist for the AChBP, and the goal of the mutations 
was to decrease affinity of ACh for the mutant receptors. In the C-loop, mutants T184F, 
S186I and S186M did not show any binding to antagonist dTC; however, the mutations 
did not affect ACh binding which indicates the basic structure of the C-loop was not 
disturbed by the mutation.
Except for T 184F, which showed a slight increase in affinity of ACh for the 
receptor, data indicated a general decrease in affinity of acetylcholine for mutated 
receptors. These results demonstrate the importance of substituted residues in binding 
of ACh to the 5-HT3 receptor, as well as decreased affinity of the ligand for receptors. 
S186I, P189S, and the three double mutations did not show any overlap in their 95% 
confidence intervals with the AChBP, signaling significant difference between these 
mutant receptors and the wild-type (Table 4.2). Since the general goal was to decrease 
affinity of acetylcholine for receptor through mutation, results showed that double 
mutations had the largest affinity decrease which might indicate that removal of the 
proximal cysteines was necessary to decrease affinity of the ACh ligand for the 
receptor.
In addition, the goal of mutation was to increase affinity of the serotonin agonist, 
serotonin (5-HT), and partial-agonists, m-chlorophenylbiguanide (mCPBG) and 2- 
Methyl-serotonin (2-Me-5HT) for the receptors. Data showed that the serotonin agonist, 
5-HT, did not bind to T184F and S186M mutants, indicating that amino acids T and S 
were involved in binding of the serotonin ligand to the AChBP. In both cases, the 
substituted amino acid was much larger than the original residue, which might not have 
left enough space for the ligand to bind. Since the mutation reduced affinity, it might 
also indicate that it decreased an interaction or altered the structure of the binding loop. 
Except for C187I/C188S, data for mutants that were tested showed a general decrease 
in affinity of 5-HT for the mutated receptors, and their 95% confidence intervals did not 
overlap with the AChBP, signaling significant differences between the mutant receptors 
and the wild-type (Table 4.2). The 5-HT ligand showed an increased affinity for the 
C187I/C188S mutant, which supported the new and alternate alignment of the C-loop 
residues.
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The result of 5-HT inhibition indicated that: a) removal of proximal cysteines is 
needed to increase affinity of the mutated receptor for the serotonin ligand since the 
highest affinity was seen in double mutations, b) depending on the original or 
substituted residue, the mutated receptor showed increased or decreased affinity for the 
ligand; therefore, mutation of the AChBP proximal cysteines to E-and-S or S-and-S did 
not increase affinity of mutated receptor for serotonin ligand, but I-and-S residue 
mutation could result in a receptor resembling the 5-HT3 receptor, and c) a new 
alignment between the AChBP and 5-HT3 receptor was needed.
Similar to data from 5-HT inhibition, the partial-agonist mCPBG did not show any 
binding to T184F and S186M mutants, indicating that amino acids T and S were 
involved in binding of the mCPBG ligand to the AChBP. In both cases, the substituted 
amino acid was much larger than the original residue, which might not have left enough 
space for the ligand to bind. Since mutation reduced affinity, it might also indicate that it 
decreased an interaction or altered the structure of the binding loop. Except for 
C187I/C188S, data for the mutants that were tested showed a general decrease in 
affinity of mCPBG for the mutated receptors, and their 95% confidence intervals did not 
overlap with the AChBP, signaling significant differences between the mutant receptors 
and the wild-type (Table 4.2). The mCPBG ligand showed an increased affinity for the 
C187I/C188S mutant, which supports the new and alternate alignment of the C-loop 
residues.
Data for 2-Me-5HT showed a general decrease in affinity of the 2-Me-5HT ligand 
for the mutated receptors. The 95% confidence intervals for none of the mutants 
overlapped with the AChBP, signaling significant differences between the mutant 
receptors and wild-type (Table 4.2). The 2-Me-5HT inhibition results showed that the 
original residues in T184F and S186M mutations might be involved in a selective 
interaction of 2-Me-5HT ligand with the AChBP. These same receptors also did not 
interact with the other serotonin partial-agonist, mCPBG, which might be due to the 
large size of the substituted residue that made it impossible for the ligand to interact 
with the mutated receptor, or the structural differences in the 2-Me-5HT binding site by 
the mutation prevented the interaction.
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Taken together, data indicates that the C187I/C188S double mutant showed 
almost no change in granisetron binding affinity, a decrease in dTC and ACh affinities, 
and an increase in serotonin agonist 5-HT and partial-agonists mCPBG and 2-Me-5HT 
affinities. It should be noted that the affinity changes were small when compared to the 
affinity of the wild-type receptor for different ligands. These small differences showed 
that the new amino acids could be substituted for the original ones in the AChBP, which 
also supported the alternate alignment of the C-loop between the AChBP and 5-HT3 
receptors.
4.7 Summary
The goal of our study was to decrease affinity of acetylcholine (ACh) and 
serotonin antagonist, and increase affinity of serotonin agonist and partial-agonist for 
the AChBP using site-directed mutagenesis, since previous data from our laboratory 
showed that the AChBP had high affinity for serotonin antagonist and low affinity for 
serotonin agonists (113).
Data indicated that the most significant changes occurred in the C-loop. Results 
for mutants showed a general decrease in affinity of ACh and serotonin antagonists, 
granisetron and d-tubocurarine (dTC) for the mutated receptors; however, no large 
changes (>10 folds) in binding was observed when compared to the wild-type AChBP, 
which indicates that there was little structural perturbation of the C-loop and binding site 
due to each individual mutation. The largest affinity decrease for the ACh was observed 
in double mutations which might indicate removal of the proximal cysteines will be 
necessary for a successful conversion of the AChBP to the 5-HT3 receptor. This is the 
first time it was shown that the proximal cysteines could be substituted with other 
residues and result in a functioning receptor.
In addition, mutation of certain AChBP residues to its equivalent in serotonin 
receptor resulted in an increased affinity of serotonin agonists and partial-agonists for 
the AChBP. Data indicated that individual mutations were not capable of increasing 
affinity of serotonin agonists for the AChBP very much; however, each individual 
mutation increased the affinity to a certain degree. The highest affinity increase was 
observed in double mutants, C187I/C188S, which indicates that removal of proximal
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cysteines was involved in increasing the affinity of serotonin ligands for the mutated 
receptor. The best residues to substitute for the proximal cysteines were ‘IS’ which 
preserved the structure of the C-loop. Therefore, based on these data, we propose a 
new alignment for the C-loop between the AChBP and the serotonin receptor.
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Chapter 5: Discussion
5.1 Introduction
The overarching goal of this thesis was to explore acetylcholine-binding protein 
(AChBP) as a potential biosensor molecule by using it as a template for development of 
a soluble binding protein analog of the serotonin type 3 (5-HT3) receptor that would be 
suitable for use in high-throughput biosensor devices. The 5-HT3 receptor is an 
important central nervous system (CNS) receptor that is the target for anti-emetic (145) 
and other potential CNS-acting therapeutic agents (15).
The specific aim of this thesis was to engineer a soluble serotonin-binding protein 
using the Lymnaea AChBP that would mimic the specificity of native human 5-HT3 
ligand-gated ion channel (LGIC) receptor. The aim of this project was approached in a 
sequential manner to achieve the following objectives:
Objective 1: Development o f stable expression o f the Lymnaea A ChBP in
mammalian cell lines, evaluation o f its application to scintillation 
proximity assay (SPA) and microcantilever assay (MC), and its 
subsequent pharmacological evaluation (Chapter 3).
Objective 2: Design and development o f mutations o f the A ChBP consistent 
with the 5-HT3 receptor-ligand interactions, designed to improve 
interactions o f the AChBP with serotonin ligands and decrease 
interactions with nicotinic receptor ligands (Chapter 4).
Objective 3: Design and development o f double mutations to determine if  the 
selectivity for serotonin ligands could be enhanced (Chapter 4).
Objective 4 : Using the data from objectives 2-and-3 to suggest new mutations 
and produce a new model to further enhance selectivity for 
serotonin ligands (Chapter 5).
Objective 1 was addressed in Chapter 3, which focused on developing the 
AChBP as a sensor protein and evaluating the structure, stability and functionality of 
this protein. SPA was used to determine how different ligands interact with the AChBP.
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This data is of value since the AChBP has been used as a template in computer 
modeling studies of the 5-HT 3 receptor (9,103,115). In addition, the AChBP protein 
produced in these studies was evaluated to determine if it could be used on a high- 
throughput microcantilever system.
Objectives 2 and 3 were addressed in Chapter 4, which focused on mutation of 
the AChBP using single and double amino acid substitutions of residues previously 
determined to be critical to interaction of the 5-HT3 receptor with serotonin ligands. All 
the mutations were expressed in stably transfected mammalian cell lines designed to 
secrete the modified AChBP proteins into the cellular medium. Mutated proteins were 
characterized by gel electrophoresis and subsequently tested for their interaction with 
different ligands.
5.2 The AChBP Mutant Data
Previous data from our laboratory identified specific amino acids that are 
important for agonist and/or antagonist binding to the 5-HT 3 receptor (113). Our 
laboratory also constructed homology models of the 5-HT3 receptor that aligned binding 
loops (A-F) between the AChBP and serotonin receptor (20,21). The alignment showed 
conservation of amino acids in all key binding loops with the exception of the A, C and E 
loops. The C-loop has been identified as a key region responsible for ligand selectivity
(18,125), thus we designed a number of single and double mutants in this more variable 
region. A single potentially important mutation was also made in the A-loop along with 
two mutations in the E-loop (Figure 4.1). All three regions have been implicated in 
ligand binding by prior studies (18,124). The AChBP residues were individually mutated 
to 5-HT3 receptor equivalent residues with the goal of increasing ligand selectivity and 
specificity of the AChBP for serotonin receptor ligands.
Previous data from our laboratory showed that the AChBP binds strongly to 
serotonin receptor antagonists, and weakly to serotonin receptor agonists (113). Since 
the serotonin antagonists already bind to the AChBP with high affinity, little change was 
expected for these ligands on the modified AChBP. In contrast, for agonists we 
expected to see improved interaction as indicated by increases in affinity of the modified 
receptor. Thus, the expected outcome of these studies was to increase the affinity of
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AChBP for serotonin agonists, and decrease or have no effect on its affinity for 
serotonin antagonists.
Representative members of major structural classes of 5-HT3 receptor ligands 
were chosen to test effects of different mutations on binding of ligands to the AChBP. 
Acetylcholine (ACh) was used as control to monitor the effect of mutations on a nicotinic 
ligand. In this case, the goal was to decrease the affinity of the AChBP for ACh when 
making serotonin receptor equivalent mutations. Granisetron and d-tubocurarine (dTC) 
were selected as antagonists since they bind to both the AChBP and serotonin receptor 
(21). Since granisetron is available in a radioligand form, it was also ideal for use in the 
SPA assays. Thus, our studies used [3H]-granisetron for binding and completion 
assays. While epibatidine is a common radioligand for use in the AChBP binding 
assays (21), we chose not to use this ligand since it is not an antagonist to both the 
AChBP and serotonin receptor, and it was anticipated that it would bind less tightly to 
the modified receptors and would not permit easy comparison across all receptors 
(native AChBP and modified AChBP) in competition assays. Serotonin (5-HT), 2- 
Methyl-serotonin (2 -Me-5HT), and m-chlorophenylbiguanide (mCPBG) ligands were 
chosen as representatives of common agonist and partial-agonists. The choice of 
multiple ligands with different structure is considered important to fully assess changes 
in selectivity (21,124) as the receptor is systematically altered by mutation of the 
AChBP. In a receptor, different degrees of C-loop closure are considered critical to 
interaction of the receptor with agonists, partial-agonists and antagonists 
(corresponding to complete closure, partial closure and no closure of the C-loop)
(124,125), and thus modification of the C-loop can potentially produce substantially 
different effects on different ligand classes.
Data in Chapter 4 indicated that the most significant differences in amino acid 
sequence, and presumably structure, appear to be in the C-loop. C-loop mutations 
produced a general decrease in affinity of mutated receptors for ACh and serotonin 
antagonists. However, individual mutations were not adequate to significantly increase 
affinity of the AChBP for serotonin agonist and partial-agonist; multiple mutations were 
necessary.
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5.3 New Mutant Constructs
A key determination of the data presented in Chapter 4 is the discovery that the 
proximal cysteines of the C-loop can be substituted with 5-HT3 receptor equivalent 
amino acids and still produce a functioning receptor, presumably with a preserved C- 
loop structure. Based on these data, we proposed a new alignment for the C-loop 
between the AChBP and serotonin receptor. Aligning the AChBP proximal cysteines 
(C187/C188) with the I-and-S amino acids of 5-HT 3 receptor (I230/S231) shift the C- 
loop alignment between the two receptors by one residue. Since Y234 of the 5-HT3 
receptor and Y192 of the AChBP were used to align the amino acid sequence of the two 
receptors, the difference between the old and new alignment is a total of three residues 
in the AChBP, of which one residue has to be eliminated to keep the tyrosines in their 
original position and in alignment with each other. The three AChBP residues for 
consideration were proline (P189), glutamate (E190) and alanine (A191). We decided 
to eliminate alanine rather than proline since prolines are typically found in tight turns 
and its presence in this loop is likely critical to the structural integrity and stability of the 
protein. Since glutamate (E190) is a hydrophilic residue, it aligns well with serine 
(another hydrophilic residue) in the 5-HT3 receptor sequence. Removal of an amino 
acid, or residue deletion, is generally expected to cause a large conformational change 
in the receptor and its binding properties.
We constructed two modified AChBPs: one with only the A191 deletion (A- 
deletion), and the other with a C187I/C188S mutation along with the A191 deletion (IS + 
A-deletion). Stable cell lines were produced for both binding proteins; however, we 
were unable to detect any protein which suggests the A-residue is important in protein 
assembly and expression. Since expressed protein should have been purified via the 
His tag added to each subunit of the receptor that bind to the nickel column and is 
pulled out the media (even in unassembled receptors), it appears that the protein was 
either not produced or was not secreted. It is possible that A-deletion altered protein 
structure, preventing protein secretion into the cellular medium. Absence of mutated 
protein could also be the result of a structural change of protein that buried the His tag 
in a misfolded protein, making it unavailable to bind to the nickel column.
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5.4 Future Directions
The goal of this section is to explore and suggest possibilities for future directions 
of this protein engineering project. While this project did not succeed in producing a 
viable analog of the 5-HT3 receptor that met the goals of the project, an engineered 
soluble receptor analog suitable for biosensor use would allow screening of wide range 
of natural products and synthetic drugs in a much shorter period of time and is still a 
valuable goal. As the cost of drug discovery is about 1/3 of the cost of developing a 
drug (https://www.fda.gov/drugs/developmentapprovalprocess/ ), this would represent a 
large cost savings. In addition, such proteins would find important uses in detection of 
bioweapons or bedside drug screenings as these receptors are important receptors for 
toxic compounds as well (109). Other important outcomes did result from this study, 
demonstrating the value of the mutagenesis approach presented here. Understanding 
of the similarities and differences between the AChBP and the 5-HT3 receptor provides 
new information about both proteins and ligand selectivity, and provides a starting point 
for the next series of experiments.
5.4.1 Mutations
In this project, we substituted residues of one receptor (AChBP) to its equivalent 
in the other receptor (5-HT3) so it could bind to certain ligands. Therefore, it was 
expected to see small changes which would mean either the substituted residue was 
not involved or the changes were so small that the substitution did not matter. Data 
showed the unique feature of the AChBP, namely the proximal cysteines which is 
important in the structure of the C-loop, could be substituted and was in fact necessary 
to increase affinity of the modified receptors for the serotonin agonist and partial- 
agonist. The C-loop is the most variable loop which is also involved in binding of 
ligands (124). The degree of C-loop closure determines whether a ligand is a full or 
partial agonist (124,125), and thus, mutation will affect the degree of C-loop closure. 
Data from double mutations suggested a new alignment for the C-loop, and using this 
new alignment, we can make multiple mutations within this group. For example:
1. Use the new alignment (IS substitution) and delete proline (P189) in the 
AChBP. In homology structures of the 5-HT3 receptor and x-ray structures of
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the AChBP protein, differences in fundamental C-loop structure are clearly 
evident (18,20). This observation and data from previous studies (113,124) 
indicate that the C-loop is critical to ligand selectivity, and the fundamental 
nature of agonists and antagonists suggest this should be a key focus of any 
further studies. The proximal cysteines (C187/C188) in the AChBP introduce 
a kink in the C-loop, and presence of proline after the proximal cysteines 
introduces another kink (1) in the same loop. Mutation of C187/C188 to IS 
would remove the first kink, and perhaps deletion of P will remove the second 
kink of C-loop, leading to a more direct interaction of the mutated receptor 
with serotonin ligands.
2. Use the new IS alignment and eliminate glutamate (E190) in the AChBP.
This mutation would align P189 residue of the AChBP which is hydrophobic 
with asparagine (N232) of serotonin receptor which is hydrophilic and capable 
of hydrogen bonding; a feature that can stabilize the AChBP-ligand complex.
As mentioned earlier in this chapter, we designed and produced a mutant that 
carried the IS substitution plus A-deletion; however, the mutant was incapable of protein 
production. This raises the question of whether the result was due to deletion of alanine 
(A191) residue in the AChBP, alignment of P189 (AChBP) with N232 (5-HT3), or 
alignment of E190 (AChBP) with S233 (5-HT3). To answer these questions, we can:
1. Construct a single mutation in the AChBP to substitute P189 with an N residue. 
This mutation will replace proline which exists in tight turns (1), and thus 
introduces a special kind of kink in a protein, with asparagine; a residue that can 
form hydrogen bond.
2. Substitute E190 in the AChBP with serine (S) residue. Both amino acids are 
hydrophilic and capable of hydrogen bonding that leads to receptor-ligand 
stabilization.
5.4.2 Optimizing Results
The next natural step in this process would be production of mutant AChBPs 
based on the data from these studies, along with new molecular modeling and site-
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directed mutagenesis studies. Mutant data could be used as a starting point to develop 
models, in which molecular determinants of interactions can be predicted from 
structures of agonists and antagonists. Modeling studies can also be aimed at 
deciphering the structural features that drive the binding affinity of the serotonin ligands, 
and in improving interpretation of the results presented in Chapter 4.
Critical information can also be obtained via determination of crystal structures 
for modified AChBPs. The production of modified, soluble AChBPs allows for more 
detailed structural analysis of the effects of mutations in the AChBP and the effects of 
these structural changes in ways that are typically not available in mutagenesis studied 
of the ligand-gated ion channel (LGIC) receptors. This will contribute towards a better 
understanding of not only the mutagenesis of these receptors, but also the effects of 
mutations on protein structures in general. These data could provide a more 
comprehensive understanding of the molecular basis for receptor and ligand 
interactions, which may aid in designing better drug candidates. Crystalized complexes 
with different agonists and antagonists could also lead to identification of structural 
features in the ligands that confer differences in their behavior. Thus, the mutant and 
associated co-crystal structures with serotonin receptor ligands provide a rich starting 
point for understanding interactions for the various LGIC receptor subtypes.
And yet another approach to optimizing results would be to consider 
contributions of other loops and different amino acids from those loops to ligand 
selectivity. Data provided by this approach will not only be the first study of its kind, but 
in general, a great contribution to this area of research. Advances in protein and DNA 
manipulation now permit mutations to be constructed using commercial mutagenesis 
services to facilitate rapid production of mutations and save time. Mutant receptors 
could then be expressed and characterized, and mutant binding proteins would be 
evaluated via attachment to a sensor platform (e.g. SPA).
5.4.3 Acetylcholine-binding Protein from Other Species
This project utilized acetylcholine-binding protein (AChBP), a protein thought to 
be secreted into the synapse by the glia of certain snails (96) and the homolog of 
extracellular domain of nicotinic acetylcholine (nACh) receptors, from the great pond
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snail Lymnaea Stagnalis (99). At the time of this project, two additional homologs of this 
protein had already been identified in the freshwater snail Bulinus truncates (98), and 
sea hare Aplysia californica (111). Since that time, another mollusk, the abalone 
Haliotis discus hannai was shown to have a functional homologue of the AChBP (146), 
and a homologue of the AChBP from the pearl oyster Pinctada fucat was found to bind 
to calcium carbonate (147). Taken together, this trend raised the assumption that the 
AChBP was limited to the aquatic mollusks and phylum Mollusca. However, recent 
identification of the AChBP in other phyla has provided more information toward 
understanding this protein and its function. For example, the AChBP has been 
identified in the marine segmented worm Capitella teleta (148) from the phylum Annelid, 
and in spider (149), from the phylum Arthropoda. The amino acid sequence for the 
newly found AChBPs is approximately 30% identical with those of known molluscan 
AChBPs (148,149). These discoveries show the AChBP exists in different phyla, and 
that it has variation in the sequence, structure and function, which raises the question of 
whether the AChBP has phylum-specific amino acid sequence or structure. It will be of 
interest to compare the C-loop of both spider and segmented worm with the L. Stagnalis 
used in this project to find if they align better with the C-loop of the serotonin receptor. 
Furthermore, the entire amino acid sequence of the AChBP for spider and segmented 
worm could be compared with different LGIC receptors to ascertain if they offer a better 
alignment than the AChBPs in mollusks. The identification of AChBP in other phyla and 
analysis of their sequence and structure will provide additional information about critical 
residues for agonist and antagonist binding.
5.4.4 Development of other LGIC Binding Proteins
Members of the cys-loop LGICs, namely nicotinic acetylcholine (nACh), glycine, 
Y-aminobutyric acid (GABA), and 5-hydroxytryptamine type 3 (5-HT3) receptors have 
been modeled based on the AChBP (9,93,113). These models have provided a wealth 
of useful information regarding binding site structure of the LGIC receptor family. 
Development, production and stability of the mutant cells in this project could be 
expanded to enable development of binding proteins for other cys-loop receptors. A 
long-term goal of this project could be to use the AChBP to develop soluble binding
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protein by mutating the key amino acids involved in ligand selectivity in different LGIC 
receptors. This would be a focused project and the first of its kind, since such mutant 
constructs can serve to enhance the use of the soluble AChBP in the template-guided 
therapeutic design of novel agents for LGIC disorders (24-28,32), as well as allow for 
fast evaluation of new drugs that might interact with these receptors.
5.4.5 Biosensor Platforms
This project utilized the scintillation proximity assay (SPA) as its preferred 
method for evaluation of competitive ligands. SPA offers a low price assay that requires 
low quantity of protein and does not have any molecular weight limitations. The primary 
disadvantage of this method was use of a radioligand, as well as the requirement of the 
competing ligand to alter the binding affinity of the radioligand. This requirement 
prohibits discovery of novel compounds that may alter receptor function by non­
competing mechanism. Nevertheless, the SPA experiments demonstrated its potential 
for high-throughput screening.
The ability of radioligand-free detection, sensitivity of the detection range, and 
scalability to allow multiple parallel detections are some of the important requirements 
for a future generation of biosensors. Two biosensor platforms that possess these 
criteria are surface plasmon resonance (SPR) and microcantilever (MC). The SPR and 
MC assays are chip-based assays have the advantage of not requiring a radioligand, 
requiring only small amounts of test compounds, and scalability to multiwall systems to 
speed analysis, and allowing the detection of binding to both orthosteric and allosteric 
binding sites (78,81). The SPR assay can obtain rate constants for both on-and-off 
rates, and older SPR approach could not determine kinetics for low molecular weight 
compounds due to its reliance on molecular weight detection, which was considered a 
major disadvantage of SPR ; however, current SPR approaches are sensitive to ligands 
with molecular weights as low as 90 kD (77,80).
Microcantilever-based biosensors have attracted much attention. They consist of 
a chip-based, label-free, real-time and highly sensitive approach to the detection of 
biomolecules. While not yet commercially available, much progress has been made in 
this field in recent years (81,118). Data shown in Chapter 3 demonstrates the viability
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of using the AChBP to produce an active microcantilever sensor that can detect 
interaction of ligands with great sensitivity. Further development of this assay would 
permit rapid screening of multiple receptors at one time using a micro sensor array.
The microcantilever system can be used to produce sensor arrays on a microchip 
containing in excess of 96 independent, addressable flow channels, and detection of 
microcantilever bending could be accomplished as integrated detection in the microchip. 
A significant finding of the microcantilever study is that the sensor detects 
conformational change in the binding protein, thus producing a larger bending for 
agonist ligands versus antagonists (118). This may provide a new way to obtain 
functional data. It seems likely that the modified AChBP proteins can be added to the 
detection arrays to permit evaluation of a single drug molecule on multiple receptors at 
the same time.
5.4.6 Protein Expression
As mentioned in previous chapters, some of the mutants in this project did not 
express any protein, and some like the chimera had a low yield that was too low to 
permit further experimentation. More recently, the important role of molecular 
chaperone proteins in LGIC assembly has become evident (150). Chaperone proteins, 
or molecular chaperones, are proteins that reversibly bind to the hydrophobic area of an 
unfolded, misfolded, or aggregated protein, and through cycles of binding and release 
help the protein attain its native and active conformation (151). In addition, since 
chaperone proteins are present in all cells, tissues and organs, they are also implicated 
in assisting proteins to translocate to their final destination (151). A new approach to 
the expression of chimeric AChBPs would be to use these molecular chaperone 
proteins to enhance expression of the AChBP constructs. Use of chaperone proteins 
could lead to increased production of the chimeric proteins, thus enabling purification, 
evaluation, and characterization of target protein.
Acetylcholine (ACh) receptor folding, assembly and trafficking in muscle and 
neurons are influenced by several chaperone proteins. The RIC-3 protein, a 
transmembrane protein resistant to inhibitors of cholinesterase is a much more selective 
chaperone for the a7-ACh receptor, which is the most abundant ACh receptor subtype
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in the mammalian central nervous system (152). The RIC-3 protein was first identified 
in the nematode, C.elegans, as a protein necessary for synaptic transmission mediated 
by neuronal ACh receptors, but not by other LGICs (153). Homologs of the gene ric-3 
have been identified, cloned and characterized in other species (e.g. insects (154), 
amphibians (155), mammalians (150)), and human RIC-3 is expressed in neurons and 
muscles (152,156), thus enabling its interactions with ACh receptors.
Co-immunoprecipitation studies have demonstrated the interaction between RIC- 
3 and the a7-ACh receptor subunit (157,158). It has been reported that RIC-3 
increases a7 expression in HEK-293 and other mammalian cell lines (152,154,158,159), 
and that difficulties in the efficient expression of a7 in some cultured mammalian cell 
lines may be due to a requirement for the RIC-3 protein (157,160). Findings of Osman 
et al. (161) supported the view that RIC-3 regulates ACh receptor trafficking by 
increasing the number of mature or correctly folded receptor subunits reaching the cell 
surface. In addition, it has been shown that RIC-3 enhances functional expression of 5- 
HT 3 receptors in a human kidney cell line (159,162-164). It seems that with the 
exception of the 5-HT3 receptor, RIC-3 appears to have little or no effect upon other 
LGICs, including those activated by GABA and glutamate (150,157,162,163). More 
recently, Kuryatov et al. (156) reported that RIC-3 alone is insufficient for optimal 
expression of functional a7; however, chemical chaperones (cholinergic ligands that can 
act as a pharmacological chaperone) can greatly increase the assembly, and upgrade 
the amount of functional a7 in a HEK-293 cell line that expressed both a7 and RIC-3.
Taken together, all collected data suggests that RIC-3 chaperone protein, and 
possibly some pharmacological chaperone, are required for the correct folding and 
expression of the a7-ACh and 5-HT3 receptors. Therefore, it is possible that 
transfection of HEK-293 cells with both the AChBP DNA and RIC-3 protein might 
optimize protein expression of the wild-type protein in the stable cell line. The amount 
of protein produced from this experiment can be compared to the original protein 
concentration. If the results are positive, the same protocol could be extended to all the 
mutated DNAs, as well as the chimera to investigate effect of molecular chaperones on 
protein expression.
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5.4.7 Protein Expression Systems
There are various protein expression systems such as bacterial (E. coli), yeast 
(S. cerevisiae), insect / baculovirus, or mammalian cells. This project utilized the HEK- 
293 cell line (human embryonic kidney cells), which is a mammalian cell expression 
system to generate mature protein (165) to be used with different biosensor platforms. 
The mammalian expression system allows post-translational modifications that can be 
important for the solubility and activity of the expressed protein (166) such as the 
AChBP; however, these expression systems are typically costly, time-consuming and 
more complex when compared to the other expression systems such as E. coli (167).
Bacterial protein expression systems are popular as bacteria are easy to culture 
and grow fast, but they are not capable of post-translational modifications (e.g. 
glycosylation) or molecular folding of the eukaryotic proteins (167). However, it was 
shown glycosylation was not important for binding properties of the AChBP (168), and 
that de-glycosylation was required to facilitate crystallization of the protein (101,111). 
With advances in the cell lines, fusion proteins and expression vectors, the E. coli 
expression systems have become an attractive option for the production of recombinant 
proteins (167,169), and most recently, an E. coli recombinant expression system 
capable of expressing the AChBPs in the soluble fractions was developed (170). 
Considering the AChBPs are routinely used for biophysical and structural studies, the 
recombinant expression system in E. coli offers a simpler, faster, cost-effective and 
high-throughput source of protein production when milligram quantities of soluble, stable 
and functional proteins are required.
The baculovirus-insect cell expression system is widely and routinely used for the 
production of recombinant proteins with modifications similar to mammalian cells 
(171,172). This expression system is based on the use of recombinant baculoviruses 
(insect viruses) and their ability to produce proteins in cultured insect cells or insect 
larvae. The genes in insect viruses can be replaced with foreign genes, thus converting 
the viruses into expression vectors which are then transfected into insect cells to 
produce recombinant proteins (173). Lin et al. (174) reported use of the baculovirus- 
insect cell expression system for high yield production of the AChBP proteins to be used 
for structural and functional studies. This expression system can be easily scaled up for
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a more convenient and high-throughput expression of proteins that are more 
functionally similar to native mammalian proteins.
5.5 General Summary and Closing Remarks
Ligand-gated ion channels (LGICs) are crucial to the function of the peripheral 
and central nervous system, and have been implicated in learning and memory, fluid 
balance, appetite control, regulation of blood flow, and pain (22). Malfunctions of cys- 
loop LGICs, like the serotonin receptor (5-HT3), are linked to various diseases and 
disorders including muscular dystrophies (23), central neurological disorders (e.g. 
autism, attention deficit hyperactivity) (24,25), neurodegenerative diseases (e.g. 
Alzheimer, Parkinson) (26-29), neuropsychiatric disorders (e.g. anxiety, depression, 
schizophrenia, epilepsy) (30,31), and nicotine, drug and alcohol addiction (32,33).
The specific goal of this project was to develop a molecular biosensor for 
serotonin through engineering a soluble, serotonin-binding protein that would mimic the 
serotonin protein. To accomplish this goal, we used a soluble acetylcholine-binding 
protein (AChBP) that is similar in sequence and structure to the membrane-bound LGIC 
family. Our approach used site-directed mutagenesis of the AChBP biding site, with the 
goal of increasing the affinity of the AChBP for serotonin ligands. Chapter 3 explored 
and confirmed the potential of the AChBP as a viable biosensor option, and Chapter 4 
presented the results of select mutations of the AChBP and our success in this 
approach.
This project was a highly ambitious protein engineering project, since it was the 
first time the AChBP was being investigated as a potential biosensor molecule for 
development of a soluble homolog of a non-nicotinic LGIC receptor. Consequently, this 
project was unique and one of its kind, high risk and very difficult, but with potentially a 
high return as it focused on the development of biosensor proteins to be used in drug 
development. It provided valuable information regarding pharmacology of the AChBP 
as a potential biosensor molecule, as well as its interactions with 5-HT3 receptor 
ligands, which was not previously available. By applying suggested strategies 
mentioned earlier in this chapter, we will be able to further identify key amino acids that 
are involved in selectivity, and reach the point of a viable serotonin biosensor. Once the
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nature of selectivity in the serotonin receptor is discovered, this knowledge can be 
applied to other receptors, leading to the development of soluble LGIC biosensors. 
These soluble biosensors can be easily attached to biosensor surfaces and be utilized 
in high-throughput drug screening, drug development, ligand detection, and synthesis of 
new ligands which will contribute to human health. In addition, sensors of this type 
could be used for in-vitro, in-vivo, and environmental biosensor applications.
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